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Parthenolide (PN) is the principal sesquiterpene lactone of feverfew (Tanacetum 
parthanium), a herbal plant that has been used for the treatment of fever, migraine, and 
arthritis in Europe for centuries.  It is well-established that PN possesses strong anti-
inflammatory activity, presumably through its known inhibitory effect on the major anti-
inflammatory pathways such as NF-κB and signal transducers and activators of 
transcription (STATs) pathways.  However, little is known about the anti-cancer property 
of PN.  Therefore, the main objective of this study is to systematically evaluate the anti-
cancer property of PN using a combination of in vivo and in vitro approaches.  The 
following studies have been conducted: (i) chemopreventive and chemotherapeutic 
potentials of PN using UVB-induced skin cancer model with SKH-1 hairless mice; (ii) in 
vitro investigation to elucidate the sensitization effect, and the underlining mechanisms of 
PN in UVB-induced apoptosis in murine epidermal cell line JB6.   
We first tested the anti-cancer effect of PN in UVB-induced skin cancer model.  
SKH-1 hairless mice fed with PN (1 mg/day) showed a delayed onset of papilloma 
incidence, a significant reduction in papilloma multiplicity (papilloma/mouse) and sizes 
when compared to the UVB-only group.  It was found that PN is as effective as 
Celecoxib, a specific COX-2 inhibitor with known chemopreventive property against 
UVB-induced skin cancer.  However, our data suggested that COX-2 is unlikely to be the 
molecular target for PN since neither the COX-2 expression nor PGE2 production is 
altered by treatment with PN.  We next investigated the molecular mechanism(s) 
involved in the anti-cancer effects of PN using cultured JB6 murine epidermal cells.  
Non-cytotoxic concentrations of PN significantly sensitize cells to UVB-induced 
 x
apoptosis.  Further investigations reveal that PN suppresses the UVB-induced JNK and 
p38 kinase activations, leading to the downstream inhibitions of c-Jun at Ser-63 and Ser-
73 as well as ATF-2.  Such suppressions are capable of inhibiting the pro-survival 
transcription factor AP-1, leading to the sensitization of cells to UVB-induced apoptosis.  
In addition, PN selectively promotes the pro-apoptotic PKCδ but suppress the anti-
apoptotic PKCζ.  More importantly, we found that PKCζ acts upstream of p38, but not 
JNK, to protect cell death induced by PN and UVB. 
In conclusion, the overall findings suggest that PN possesses strong 
chemopreventive property against UVB-induced skin cancer as supported by solid in vivo 
and in vitro evidences.  These novel findings may shed new light in understanding the 
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1.1  Parthenolide 
Feverfew (Tanacetum parthenium) has been used as a herbal medicine for the 
treatment of fever, arthritis, and migraine in Europe for centuries.  The crude extracts of 
this herb is known to have anti-microbial and anti-inflammatory properties (Brown et al., 
1997; Jain and Kulkarni, 1999).  The principal active component in feverfew is the 
sesquiterpene lactone (SL) parthenolide (PN).  The prefix “sesqui” indicates SLs are 15-
carbon terpenoids while the suffix “olide” specifies the presence of a lactone group.  
Indeed, PN contains a highly electrophilic α-methylene-γ-lactone ring and an epoxide 
residue capable of interacting rapidly with nucleophillic sites of biological molecules 








  Figure 1.1 Chemical structure of PN 
 
At present, there is some preliminary evidence showing the anti-cancer property 
of PN.  For instance, PN is a potent inhibitor of DNA synthesis and cell proliferation in a 
number of cancer cell lines (Woynarowski and Konopa, 1981; Hall et al., 1988; Ross et 
al., 1999).  Patel and coworkers (2000) have reported that PN sensitizes breast cancer 
cells to chemotherapeutic agent paclitaxel via its inhibitory effect on nuclear factor kappa 
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B (NF-κB).  Wen and colleagues (2002) demonstrated that PN-induced apoptosis 
involves caspase activation and mitochondria dysfunction in hepatoma cells.  Recent 
studies in our laboratory by another graduate student also demonstrated the anti-cancer 
property of PN at the cellular level (Zhang et al., 2004a, 2004b, 2004c). Here we would 
like to systematically discuss the bioactivity of PN, with a focus on its potential anti-
cancer effect. 
 
1.1.1 The Metabolism and bioavailability of PN 
At present, the metabolism of PN has not been extensively studied.  A study by 
Galal and coworkers (1999) illustrated that microbial transformation of PN by Rhizopus 
nigricans, Streptomyces fulvissimus and Rhodotorula rubra yielded a common metabolite 
14-hydroxy-11 βH-dihydroparthenolide.  On the other hand, an investigation of BF3-
mediated rearrangements of PN provided micheliolide as a major product (Castaneda-
Acosta et al., 1993).  Currently, there is no in vivo report on the bioavailability of PN.  
Using Caco-2 human colonic cells as in vitro model of the human intestinal mucosal 
barrier, it was found that PN is effectively absorbed through the intestinal mucosa via a 
passive diffusion mechanism (Khan et al., 2003).    
 PN is a relatively safe compound with few side effects.   It has been demonstrated 
that up to 4 mg of PN given daily as an oral tablet is well tolerated without dose-limiting 
toxicity (Curry et al., 2004).  The major side effect of PN is contact allergy.  PN has been 
identified to be the main content in feverfew to elicit the delayed hypersensitivity effect 
(Hausen and Osmundsen, 1983).  In recent years, PN has been used as a screening agent 
for Compositae allergy (Orion et al., 1998). 
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 1.1.2 The biochemical properties of PN 
1.1.2.1 Reaction with thiols 
Thiols (mercaptanes) comprise a class of organic compounds characterized by a 
sulphydryl group (C-SH). The intracellular biological thiols (or biothiols) can be 
classified into low molecular weight free thiols such as glutathione (GSH), and high 
molecular weight protein thiols (Parker, 1995).  It has been shown that biothiols play a 
key role in (1) maintaining the spatial structure of key regulatory proteins and the 
bioactivity of many cellular enzymes, (2) balancing the intracellular reduction/oxidation 
status (redox), and (3) acting as antioxidants (Parker, 1995; Deneke, 2000; Paget and 
Buttner, 2003; Sen, 2000).  
PN contains an α-methylene-γ-lactone moiety that is highly reactive with cellular 
thiols, resulting in alkylation of sulphydryl residues through Michael type addition.  
Under physiological condition, PN is readily released from its GSH-adduct and then react 
with its protein target (Schmidt et al., 1999), causing the depletion of protein thiols 
(Zhang et al., 2004a).  The interaction between PN and its protein targets leads to 
changes in spatial structure and binding capability of proteins and thus inhibits its 
bioactivity (Garcia-Pineres et al., 2001).  Therefore it is believed that depletion of protein 
thiols by PN has important implications in its bioactivity. 
Another important consequence of intracellular thiol depletion is the disruption of 
the cellular redox balance and induction of oxidative stress. In aerobic organisms, 
reactive oxygen species (ROS) are constantly produced during aerobic respiration. Thus, 
a highly regulated antioxidant defense system that consists of a range of enzymatic 
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proteins and non-enzymatic molecules (such as GSH) has evolved to avoid the potential 
oxidative damage. The intracellular reduction/oxidation status (redox) is a precise 
balance between levels of ROS generation and endogenous thiol buffers existing in the 
cell (Davis et al., 2001). Enhanced ROS production and/or impaired antioxidant defense 
function will lead to oxidative stress, a status closely associated with many pathological 
processes in the cell (Halliwell, 1991).  In cancer cells treated with PN, elevated levels of 
ROS has been observed and found to be closely associated with apoptotic cell death 
(Wen et al., 2002; Zhang et al., 2004a).  It is well known that the mitochondrial 
respiratory chain is the major production site of intracellular ROS. Both the 
mitochondrial structural integrity and function are subject to a preferential redox 
condition. The severe oxidative stress conferred by PN-induced thiol depletion results in 
a disruption of the integrity of mitochondria and triggers mitochondrial permeability 
transition and release of mitochondrial pro-apoptotic proteins (cytochrome c, Smac, etc.) 
which then promote apoptosis (Wen et al., 2002; Zhang et al.. 2004a). 
 
1.1.2.2 Selective effects on cell proliferation and differentiation  
It has been well established that tumor development is closely associated with 
dysregulation of the cell cycle control mechanisms through either over-expression or 
activation of cyclin-dependent kinases (CDK) and/or genetic loss/inhibition of CDK 
inhibitors (Evan and Vousden, 2001) resulting in uncontrolled cell cycling and 
unremitting cell proliferation. Thus targeting cell cycle regulators is an important and 
promising approach for cancer therapy (Carnero, 2002).  PN has been reported to arrest 
cell cycle progression at the G2/M checkpoint, especially at low concentrations in an 
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invasive sarcomatoid hepatocellular carcinoma cell line (SH-J1) (Wen et al., 2002).  In 
addition, PN has been shown to work synergistically with other chemotherapeutic drugs 
to potentiate the differentiation of leukemia cells (Kang et al., 2002; Kim et al., 2002), a 
process known to be important in oncogenesis such as the development of leukemia 
(Tsiftsoglou et al., 2003).  This promotion of differentiation suggests the potential of PN 
as promising anti-cancer agents in leukemia therapy.    
 
1.1.2.3  Induction of apoptosis 
Apoptosis is a highly regulated cell death process in eukaryotic cells to eliminate 
unwanted or potentially harmful cells during development and tissue homeostasis 
(Hengartner, 2000).  The detailed mechanisms of apoptosis will be discussed in later 
sections. 
Similar to other anti-cancer agents, the ability to induce apoptosis in cancer cells 
is one of the important mechanisms involved in the anti-tumor property of PN. Although 
the detailed molecular mechanisms have not been fully elucidated, it is believed that the 
α-methylene-γ-lactone structure is essential for the apoptogenic activity of PN. Once 
inside the cells, the thiol-reactive PN quickly conjugates with GSH and depletes 
intracellular thiols, leading to the disruption of cellular redox status and induction of 
oxidative stress (Wen et al., 2002; Zhang et al., 2004a). The excessive amount of ROS 
and disrupted redox status then cause the initiation of the mitochondria-dependent 
apoptosis pathway.  It has been shown that PN triggers mitochondrial membrane 
transition, loss of mitochondrial membrane potential and release of pro-apoptotic 
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cytochrome c, which subsequently leads to caspase activation and apoptotic cell death 
(Wen et al., 2002).   
 
1.1.2.4 Sensitization effect 
In cancer chemotherapy, combinations of different chemotherapeutic agents are 
an effective approach to overcome chemo-resistance in certain cancer types. Several 
recent studies provide evidence that PN sensitizes human cancer cells to 
chemotherapeutic drugs. For instance, pretreatment with PN significantly increased the 
paclitaxel-induced apoptosis in breast cancer MDA-MB-231 cells (Patel et al., 2000).  
Similar sensitization effects by PN were also observed in other cancer cell models 
(Nakshatri et al., 2004; Zhang et al., 2004b).  This sensitization effect by PN is mainly 
due to the depletion of intracellular thiols and ROS generation or the inhibition of the 
anti-apoptotic NF-κB signaling pathway.  In some cancer cells, the NF-κB signaling 
pathway is constitutively activated and consequently leads to overexpressions of a variety 
of NF-κB regulated anti-apoptotic proteins, such as Inhibitors of Apoptosis (IAPs), Bcl-2, 
and FLICE inhibitory proteins (FLIPs) (Kucharczak et al., 2003).  Such a mechanism 
well explains the sensitization effect of PN on paclitaxel-induced apoptosis in breast 
cancer cells with constitutively high level of NF-κB activation (Patel et al., 2000).  Some 
cell death ligands, such as TNF, are known to trigger the death receptor pathway with 
simultaneous activation of the anti-apoptotic NF-κB pathway (Schutze et al., 1995). PN 
pretreatment is able to block NF-κB activation and then sensitizes TNF-mediated 
apoptotic cell death in human cancer cells (Zhang et al., 2004b).  In addition to TNF, a 
similar sensitization effect by PN has also been found in TRAIL-induced apoptosis, via 
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modulation of the c-Jun N-terminal kinase (JNK) signaling pathway (Nakshatri et al., 
2004).  Sustained activation of JNK has also been shown to play a critical role in the 
sensitization effect of PN in TNFα-induced apoptosis (Zhang et al., 2004b). 
 
1.1.2.5 Anti-inflammatory effect 
It is generally believed that chronic inflammation promotes cancer development 
in many cancers such as breast, colorectal, and skin cancer (Coussens and Werb, 2002). 
Many anti-inflammatory drugs such as the nonsteroidal anti-inflammatory drugs 
(NSAIDs) have been confirmed to reduce the risk of colon cancer formation in both 
animal cancer models as well as in epidemiological investigations (Coussens and Werb, 
2001).  Indeed, anti-inflammatory activity is a prominent bioactivity observed in PN, 
which is often associated with its ability to inhibit NF-κB and thus to down regulate 
many of the NF-κB-dependent inflammatory responsive genes such as interleukins (IL) 
(Mazor et al., 2000), cyclooxygenase (COX) (Whan et al., 2001), and inducible nitric 
oxide synthase (iNOS) (Wong and Menendez, 1999).   
Interleukins are a big family of cytokines that play a pivotal role in inflammatory 
processes. As a potent inhibitor of NF-κB, PN significantly suppressed the expression 
and secretion of various interleukins including IL-2, IL-4, IL-8 and IL-12 (Mazor et al., 
2000; Kang et al., 2001; Li-Weber et al., 2002).  In addition, PN also suppresses IL-6 
secretion and signaling via the inhibition of signal transducers and activators of 
transcription (STATs) phosphorylation and activation (Sobota et al., 2000). On the other 
hand, nitric oxide (NO) is another important regulatory molecule involved in the 
inflammatory response. Synthesis and release of NO are mediated by iNOS. It is known 
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that PN suppresses the gene expression of iNOS in several cell lines under stimulation by 
LPS, interferon-γ (INFγ) or 12-o-tetradecanoylphorbol-13-acetate (TPA) (Fukuda et al., 
2000).   
Cyclooxgenase (Cox) catalyzes the metabolism of arachidonic acid to 
prostaglandins (PG).  There are two isoforms of Cox enzyme: Cox-1 and Cox-2.  Cox-1 
is the constitutive isoform present in most tissues and mediates the synthesis of PGs for 
the normal physiological functions.  Cox-2 is not detectable in most normal tissues but is 
induced by cytokines, growth factors, oncogenes, and tumor promoters (Kujubu et al., 
1991; Jones et al., 1993; DuBois et al., 1994; Xie and Herschman, 1995).  Many studies 
have shown that skin cancer is one of the cancers with high expression of Cox-2 
(Buckman et al., 1998; Chan et al., 1999; Higashi et al., 2000; Kanekura et al., 2000; 
Athar et al., 2001).  Furthermore, it has been demonstrated that UVB exposure induces 
Cox-2 expression both in vivo and in vitro (Buckman et al., 1998; Isoherranen et al., 
1999).  Pentland and co-workers (1999) illustrated that oral administration of a selective 
Cox-2 inhibitor, Celecoxib, reduced the tumor number and multiplicity in UVB-treated 
SKH-1 hairless mice.  In colorectal cancer model, COX-2 was shown to promote cancer 
development by suppressing apoptosis, facilitating angiogenesis, and enhancing 
metastatic potential cancer cells (Gupta and Dubois, 2001).  In summary, the ability of 
PN to suppress the COX-mediated pathway is either through directly inactivating COX-2 
enzyme activity via interaction with sulphydryl groups on enzymes (Pugh and Sambo, 
1988; Hwang et al., 1996), or by indirectly inhibiting COX-2 transcription through NF-
κB (Hehner et al., 1998).  
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1.2 UVB-induced skin cancer and the molecular mechanisms 
Solar ultraviolet radiation (UV) wavelength range borders at the violet end of the 
visible light range at 400 nm.  Wavelength ranges from 400 to 320 nm is classified as 
UVA.  UVB ranges from 320 to 280 nm, and UVC ranges from 280 to 200 nm.  No 
radiation of wavelengths shorter than 290 nm reaches the earth surface because of the 
absorption in the atmosphere by oxygen and ozone.  UVB is absorbed by the epidermis, 
resulting in epidermal cell damage, repair and hyperkeratosis (thickening of the stratum 
corneum).  In contrast, UVA leads predominantly to dermal effects and does not cause 
epidermal thickening (Pearce et al., 1987). In general, shorter UV wavelength tends to be 
stronger carcinogen when compare to the longer wavelength.  UV, especially in the UVB 
range, has been shown epidemiologically and demonstrated experimentally to be the 
major cause of skin cancer in both human and animals.   
Skin cancer is the most common type of cancer among Caucasians.  According to 
the Singapore Cancer Society, skin cancer is the 7th most common cancer in both men 
and women in Singapore.  Skin cancer can be categorized into two groups: malignant 
melanoma and non-melanoma skin cancer (NMSC).  Malignant melanoma is relatively 
rare but a more severe form of skin cancer.  It is derived from the melanocytes (pigment 
cells) in the skin.  This type of tumor can grow extremely aggressive and metastasize 
very rapidly.  NMSC is the more common type of skin cancer that includes squamous cell 
carcinoma (SCC) and basal cell carcinoma (BCC).  These skin cancers stem from the 
epithelial cells that form the epidermis.  This part of the skin absorbs most of the 
carcinogenic UV radiation.  SCC is a neoplasm of epidermal cells that differentiate 
toward keratin formation, and in advance stages, it will lose the structural organization 
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and the cells may become spindle shaped.  Typically, SCC is invasive and more than 
10% will metastasize (Kwa et al., 1992).  In contrast, basal cell carcinomas (BCC) can be 
locally invasive and destructive (Miller, 1991).  BCC is composed of undifferentiated 
cells from the germinal, basal layer of the epidermis.  In most cases, NMSCs are removed 
in an early stage of development and thus far less dangerous than malignant melanoma. 
 The mechanism(s) of UVB-induced skin cancer has not be fully elucidated.  
Many molecular cascades and targets have been proposed and are described as follow. 
 
1.2.1 DNA damage 
It is believed that DNA damage induced by UV initiates the carcinogenesis 
process.  UV produces a number of DNA lesions, with cyclobutane-type pyrimidine 
dimers (CPD) being the major one.  CPD may be formed by covalent interaction of two 
adjacent pyrimidines in the same polynucleotide chain.  Another type of UV-induced 
DNA lesion is the pyrimidine-pyrimidone, or (6-4) lesions.  The (6-4) adducts include TC, 
CC, and TT sequences.  Generally, TC lesions occur with greater frequency than CC, and 
TT lesions occur only at very high UV doses.  These lesions occur at a frequency that is 
several-fold less than CPD formation.  Other types of damage may also occur, for 
example, single strand breaks, DNA crosslinks, and purine photoproducts (for review, see 
Ravanat et al., 2001).  Both CPD and (6-4) lesions distort the DNA helix.  The ability of 
UV light to damage a given base is based on the flexibility of the DNA.  Sequences that 
favor bending and unwinding are likely sites for damage formation.  For instance, the 
possibility of CPD formation is much higher in single-stranded DNA (Becker and Wang, 
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1989) at the flexible ends of poly (dA) (dT) tracts, but not at their rigid center 
(Lyamichev, 1991). 
The significance of these DNA lesions depends upon the capacity of the cell to 
repair the damage before it can be incorporated into the genome.  Typically, DNA 
damage is repaired at a relatively high rate in human cells by the nucleotide excision 
repair (NER) mechanisms (Thoma, 1999).  NER is divided into two subpathways: 
transcription-coupled repair (TCR) and global genome repair (GG).  The TCR-NER 
represents the preferential repair of transcribed strands in active genes, while GG-NER 
refers to repair in non-transcribed parts of the genome that includes the non-transcribed 
strand of transcribed genes.  The first step in NER is damage recognition where lesions 
are identified in linker DNA that is not protected by chromosomal proteins.  The next 
step in NER is the open complex formation and damage verification.  This process 
requires more space (about 100 bp of DNA) to exercise (Huang and Sancar, 1994), and 
this may be provided by chromatin remodeling.  After excision of the damaged 
nucleotides, new DNAs are synthesized by DNA polymerases for repair purposes.  
Finally, DNA is completely restored by the ATP-dependent activity of DNA ligand (for 
review, see Thoma, 1999; Costa et al., 2003).   
  
1.2.2 NF-κB  
NF-κB is a transcription factor involved in the regulation of various important 
cellular functions including immune response and cell growth, cell death and 
development.  The active NF-κB complex is either a homo- or heterodimer consist of 
proteins from the NF-κB/RelA family.  Five members of the mammalian NF-κB/RelA 
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proteins of two classes have been cloned and characterized (Karin and Ben-Neriah, 2000).  
The first class includes p65 (RelA), RelB, and c-Rel proteins that are synthesized as 
mature products and do not require proteolytic processing.  The second class is encoded 
by NFκB1 and NFκB2 genes, and their products are first synthesized as large precursors 
p105 and p100.  Upon further proteolytic processing, these precursors will yield the 
mature p50 (NFκB1) p52 (NFκB2) proteins.   
As illustrated in Figure 1.2, NF-κB is bound to the inhibitory protein IκB in the 
cytoplasm in normal unstimulated cells.  When cells are activated, the serine-specific IκB 
kinase (IKK) complex will phosphorylate IκB at serine residues 32 and 36 (Brown et al., 
1995; DiDonato et al., 1996).  The IKK complex consists of two catalytic subunits: IKKα 
and IKKβ that can phosphorylate IκB, and one regulatory subunit IKKγ.  The 
phosphorylated IκB will be recognized by E3RSIκB, a receptor component of a SCF 
ligase family type E3, leading to the polyubiquitination of IκB and subsequent 
degradation by the 26S proteasome (Karin and Ben-Neriah, 2000).  After dissociation 
from IκB, NF-κB is then translocated into the nucleus and binds to specific DNA binding 
site and consequently modulates gene expression.   
The functional role of NF-κB in skin physiology and pathology has been well 
appreciated.  In normal murine skin, the p50 subunit of NF-κB is found in the cytoplasm 
of basal keratinocytes.  In contrast, p50 is translocated into the nucleus in the suprabasilar 
keratinocytes where cells undergo differentiation.  This suggests that NF-κB is activated 
concomitant with the time at which basal epidermal cells exit cell cycle and enter 
terminal differentiation (Seitz et al., 1998).  The process allows the establishment of the 
epidermal barrier that is essential to keep bodily fluids in and harmful microorganisms 
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out.  The same study showed that overexpression of p50 and p65 causes profound 
epidermal thinning, whereas blocking of NF-κB activity results in epidermal hyperplasia.  
Both conditions are associated with early death in the transgenic mice.  By targeting IκB 
kinase, the regulator of NF-κB, similar phenotypes have been produced in which 
blocking of NF-κB activation was associated with pathologically thickened murine 
epidermis (Hu et al., 1999; Li et al., 1999; Takeda et al., 1999).  These in vivo results 
suggest that NF-κB plays an important role in modulating the phenotype of epidermal 
keratinocytes.  In addition, NF-κB activation in the epidermis has been shown to protect 
against apoptosis (Chaturvedi et al., 1999; Seitz et al., 2000).  Seitz and coworkers (2000) 
illustrated that blockage of NF-κB activation enhances the susceptibility of normal 
epithelial cells to TNF-α and Fas-induced apoptosis, presumably via suppressed 
expression of antiapoptotic factors such as TRAF1, TRAF2, c-IAP1, and c-IAP2.   
It is believed that UV activates NF-κB (Devary et al., 1993) through a distinct 
pathway.  For instance, the UV-induced IκB degradation is not mediated through the 
phosphorylations of Ser-32 and Ser-36, a mechanism used by TNF-α or IL-1α.  
Furthermore, the activation of NF-κB induced by UV is believed to act in an IKK-
independent manner (Li and Karin, 1998; Bender et al., 1998).  In addition, some studies 
have looked into the role of TNF-α receptors in UVB-induced skin tumor and NF-κB 
signaling pathway.  Starcher (2000) showed that the absence of either TNFR1 or TNFR2 
significantly reduced skin tumor in response to UVB irradiation. Tobin and colleagues 
(1998) demonstrated that NF-κB activation by UVB in keratinocytes causes a rapid 





Figure 1.2 A schematic model of various stimuli including UV-induced NF-κB 




dominant negative TNFR1 or TRAF-2 protein could both lead to an inhibition of UVB-
induced Rel-dependent transcription.  The work showed that UVB-induced activation of 
NF-κB via TNFR1 is a key component in the UV response in keratinocytes.   
 
1.2.3 Activator protein (AP)-1  
Activator Protein-1 (AP-1) has been shown to be an important transcription factor 
in UV-induced signal transduction.  The mammalian AP-1 transcription factor complex 
consists of either homodimers or heterodimers of Jun (c-Jun, JunB, JunD), Fos (c-Fos, 
FosB, Fra-1, Fra-2), Jun dimerization partners (JDP1 and JDP2), and the closely related 
activating transcription factors (ATF2, LRF1/ATF3 and B-ATF).  Jun proteins can form 
stable homodimer, while Fos forms heterodimer with Jun.  The resulting AP-1 complex 
can then binds to and transactivates from a cis element called the TPA-response element 
(TRE).  On the other hand, ATF proteins form homodimers as well as heterodimers with 
Jun that preferentially bind to cAMP responsive elements (CRE) (Karin et al., 1997; 
Shaulian and Karin, 2001).   
AP-1 activity is stimulated by many physiological stimuli such as growth factors 
(Wu et al., 1989; Lamb et al., 1997), tumor promoters (Hashimoto et al., 1990; Domann 
et al., 1994; Huang et al., 1997), TNF-α (Brenner et al., 1989), and interleukin-1 
(Goldgaber et al., 1989; Muegge et al., 1989).AP-1 regulates the transcription of many 
genes involved in cell proliferation, apoptosis, metastasis, and cellular metabolism 
(Angel et al., 2001; Jochum et al., 2001; Ozanne et al., 2000).  The role of AP-1 in tumor 
promotion is supported by the fact that viral and cellular Jun or Fos can cause malignant 
transformation in fibroblasts (Lamb et al., 1997; Suzuki et al., 1994).  Gene products 
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promoting invasion and metastasis are also under AP-1 regulation (Lamb et al., 1997).  
Skin tumor cell lines that show constitutive AP-1 activity lose their ability to form tumors 
on s.c. injection when transfected with a dominant negative Jun mutant (Domann et al., 
1994).  When AP-1 is blocked during tumor promotion, transformation is also inhibited 
(Huang et al., 1997).   
   Short wavelength ultraviolet (UV) radiation such as UVB (Ghosh et al., 1993) 
and UVC (Adler et al., 1996; Karin et al., 1998) can also stimulate AP-1 activity.  UVB 
induces c-Fos mRNA and protein levels, AP-1 binding and transactivation in HaCaT 
cells (Garmyn et al., 1992; Ghosh et al., 1993).  It has been shown that UV induced JNK 
activation, leading to phosphorylation of c-Jun and ATF2 to enhance their transcriptional 
capacity (Gupta et al., 1995; Karin, 1995).  Wisdom and coworkers (1999) demonstrated 
that c-Jun protects fibroblasts from UV-induced cell death and cooperates with NF-κB to 
prevent apoptosis induced by TNF-α.  In addition, Huang and colleagues (1999) showed 
that Erks is required for UV-induced AP-1 activation in mouse JB6 cells.  These findings 
suggest AP-1 plays an important role in the UV response in addition to being involved in 
mitogenic and proinflammatory responses. 
 
1.2.4 Mitogen-activated protein kinase (MAPK) 
Mitogen-activated protein kinases (MAPKs) are a superfamily of enzymes that 
play key roles in transmitting signals from the membrane or cytoplasm to the nucleus 
(Seger and Krebs, 1995).  Mammals express at least four distinctly regulated groups of 
MAPK: 1) extracellular signal-regulated kinases (ERKs); 2) c-Jun N-terminal kinases 
(JNKs); 3) p38; and 4) ERK5 (Chang and Karin, 2001).  They are structurally related but 
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biochemically and functionally distinct.  In Erks cascade, MAP/ERK kinase kinase 
kinases (MKKKs) phosphorylate and activate MAPK/ERK kinases MEK-1 and MEK-2.  
These in turn activate ERKs by dual phophorylation on tyrosine and threonine residues 
(Marshall, 1994).  Growth factors and phorbol esters primarily activate ERKs, whereas 
stress or inflammatory cytokines are only poor activators of ERKs (Whitmarsh et al., 
1995; Xia et al., 1995).  It has been established that the ERK signaling response is critical 
for keratinocyte proliferation, clonal formation, and survival (Geilen et al., 1996).  Peus 
and coworkers (1999) showed that ERK 1/2 are rapidly and strongly activated within 
minutes of UVB exposure in human keratinocytes.   
In contrast, both p38 and JNK are poorly activated by epidermal growth factor 
and phorbol esters, but readily activated by a wide range of cellular stress factors such as 
osmotic shock, heat shock, inflammatory cytokines, and UV light (Peus et al., 1999; 
Rouse et al., 1994; Raingeaud et al., 1995; Derijard et al., 1995; Wesselborg et al., 1997).  
P38 can be phosphorylated and activated via MEK kinase kinase 3, 4 and 6 and small 
GTP-binding proteins such as Cdc42 and Rac (Lamarche et al., 1996; Derijard et al., 
1995; Raingeaud et al., 1996).  MEK 4 and 7 have been shown to phosphorylate and 
activate JNK.  Like other members of MAPK family, both p38 and JNK requires 
threonine and tyrosine phosphorylation for their enzymatic activities (Raingeaud et al., 
1995).  It has been shown that UVB induces transient and rapid JNK activation within 
minutes of irradiation (Peus and Pittelkow, 2001).  ERK5, on the other hand, is activated 
by MEK-5.  The exact role of ERK5 signaling pathway is yet to be elucidated. 
As illustrated in Figure 1.3, one or more MAPKKs catalyze the phosphorylation 































Figure 1.3 General overview of the UV-induced MAPK signaling cascade 
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MAPKs translocate to the nucleus where they phosphorylate target transcription factors 
such as AP-1.   
 
1.2.5 Protein kinase C 
Protein kinase C (PKC) is a group of serine/threonine kinases that regulate many 
cellular functions such as proliferation, differentiation, transformation, survival and 
apoptosis (Yang and Kazanietz, 2003).  PKC can be classified into 3 groups based on the 
co-factors required for activation: 1) the Ca2+ and diacylglycerol (DAG)-dependent 
classical or conventional PKC that consists of isotypes α, β1, β2 and γ; 2) the DAG-
dependent, Ca2+-independent novel PKC that consist of δ, η, ε and θ, and 3) the DAG- 
and Ca2+-independent atypical PKC that consist of ι/λ and ζ.   
It has been shown that the UVB-induced AP-1 activation may involve certain 
types of PKCs (Huang et al., 1996; 1997; 2000a).  UVB induces the translocations of 
PKC δ and PKCε from the cytosol to membrane, an indication of their activations (Chen 
et al., 1999).  The UVB-induced activations of ERK and JNK were strongly inhibited by 
dominant-negative mutants of PKC δ and PKCε as well as rotterlin, a specific inhibitor of 
PKC δ.  The result of such inhibition leads to suppressed UVB-induced apoptosis and 
thus suggested both PKC δ and PKCε mediate UVB-induced signal transduction and 
apoptosis through the activations of ERK and JNK (Chen et al., 1999).  Furthermore, 
inhibition of PKCλ/ι with a dominant negative mutant suppressed UVB-induced ERK 
and the subsequent AP-1 activation (Huang et al., 1996).  On the other hand, antisense 
oligonucleotide of PKCζ has been shown to inhibit the UVB-induced AP-1 activation 
(Huang et al., 2000a). 
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The consequences of PKC activation by UVB is rather cell type specific and 
could lead to inhibition on cell proliferation or even induction of apoptosis.  Among all, 
PKCδ seems to be the main PKC subtype with pro-apoptotic functions in response to 
various extracellular stimuli including UVB (Chen et al., 1999; Brodie and Blumberg, 
2003) whereas PKCζ has been shown to be anti-apoptotic in response to UV (Berra et al., 
1997; Frutos et al., 1999). 
 
1.2.6 PI3-K and AKT 
Another important signaling pathway in tumorigenesis involves the 
phosphatidylinositol-3 kinase (PI-3K).  PI-3K is known to mediate a broad range of 
biological effects that include cell proliferation, survival and adhesion, organization of 
cytoskeleton, and glucose metabolism (Hu et al., 1995; Jhun et al., 1994; Rodriguez-
Viciana et al., 1996; Leevers et al., 1999; shepherd et al., 1998).  PI-3 K dimer consists 
of a catalytic subunit P110 and a regulatory subunit P85 (Carpenter et al., 1990).  The 
P85 regulatory subunit has no catalytic activity but possesses two Src homology 2 
domains and a Src homology 3 domain (Kapeller and Cantley, 1994).  A region between 
the two Src homology 2 domains of P85 binds the NH2 terminus of P110, mediating the 
constitutive association of the two subunits (Kapeller and Cantley, 1994).   
The role of PI metabolism in tumorigenesis was implied in observations that the 
regulatory subunit of PI-3K was able to interact with certain oncogenes directly.  These 
interactions were shown to be responsible for the associated PI-3K activity (Kaplan et al., 
1987; Serunian et al., 1990).  A study by Chang and coworkers (1997) showed an 
oncogenic form of the catalytic subunit of PI-3K that was cloned from a retrovirus could 
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cause hemangiosarcomas in chickens and induce transformation of chicken embryo 
fibroblasts.  Furthermore, Shayesteh and colleagues (1999) demonstrated the 
amplification of the human gene encoding the p110α catalytic subunit of PI-3K in 
ovarian cancer tissue samples and cell lines.   
It has been shown that UVB irradiation activates PI-3K, suggesting a possible role 
of PI-3K in UVB-induced skin cancer (Kabuyama et al., 1998; Nomura et al., 2001a).  
Furthermore, changes in the activity of PI-3K signaling pathway due to the dysregulation 
of certain downstream PI-3K components such as Akt (PKB) in many cancers further 
elaborates the importance of PI-3K signaling pathway in tumorigenesis.  
On the other hand, the serine-threonine kinase Akt (or protein kinase B) is 
activated by a variety of growth stimuli including epidermal growth factor and insulin 
through PI-3K (Burgering and Coffer, 1995; Shepherd et al., 1998).  In quiescent or 
unstimulated cells, Akt resides within the cytosol in a catalytically inactive state.  Once 
activated, the phospholipids (PI-3,4,5-P3 or PI-3,4-P2) produced by PI-3K will bind to the 
PH domain of Akt kinases and trigger the translocation of Akt to the plasma membrane.  
Upon membrane localization, Akt molecules are phosphorylated at Thr-308/309 in the 
kinase activation loop and Ser-473/474 carboxyl-terminal tail.  The phosphorylation at 
Thr-308/309 is necessary for Akt activation whereas Ser-473/474 phosphorylation is only 
required for maximal activity (Bellacosa et al., 1998).  PDK-1 (3-phosphoinositide 
dependent kinase-1), which is activated by PI-3,4,5-P3 and PI-3,4-P2, phosphorylates Akt 
at Thr-308/309.  On the other hand, the putative PDK-2 phosphorylates Akt at Ser-
473/474 (Alessi et al., 1996; 1997; Chan and Tsichlis, 2001).   
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Akt has been shown to control intracellular pathways responsible for preventing 
cell death in response to a variety of extracellular stimuli (Marte and Downward, 1997; 
Dudek et al., 1997; Kulik et al., 1997).  Notably, Akt phosphorylates Bad at Ser-136.  
This phosphorylation facilitates Bad binding to protein 14-3-3 and thus neutralizes the 
apoptotic effect of Bad (Datta et al., 1997).  Recent studies suggested that Akt is not only 
a “cell survival” kinase, but it may play an important role in other cellular functions.  Akt 
phosphorylates and inactivates glycogen synthase kinase 3 (GSK-3) and thereby 
stimulates glycogen synthesis (Cross et al., 1995).  Akt activation also affects cell 
progression through regulation of cyclin D stability (Muise-Helmericks et al., 1998) and 
inhibition of p27Kip1 protein levels (Collado et al., 2000; Medema et al., 2000).  In 
addition, Akt mediates the activation of endothelial nitric oxide synthase, an important 
modulator of angiogenesis and vascular tone (Fulton et al., 1999; Dimmeler et al., 1999).  
The activation of Akt also enhances telomerase activity via phosphorylation of the human 
telomerase reverse transcriptase subunit (Kang et al., 1999).   
Furthermore, identification of gene encoding Akt as a transforming oncogene that 
causes thymic lymphomas in mice suggests a role for Akt in tumorigenesis (Bellacosa et 
al., 1991).  Overexpression of Akt has been demonstrated in many cancers in human, for 
instances, ovarian (Cheng et al., 1992), pancreatic (Cheng et al., 1996), and breast 
cancers (Bellacosa et al., 1995).  Mutations of tumor suppressor gene PTEN, which 
directly antagonizes PI-3K, have been observed in some human cancers (Li and Sun, 
1997; Steck et al., 1997).  The alteration of PTEN causes elevated phosphorylation of 
Akt (Dahia et al., 1999; Davies et al., 1999; Suzuki et al., 1998).  Recently, PTEN has 
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been shown to sensitize glioblastoma cells to chemotherapy (Mayo et al., 2002).  In 
addition, it has been shown that UVB irradiation induced Akt phosphorylation at both 
Thr-308 and ser-473 (Nomura et al., 2001b).  Their results illustrated that Erks and p38 
of the MAP kinase family mediate UVB-induced Akt activation via Msk1 (mitogen and 
stress activated protein kinase-1).  Mayo and Donner (2001) showed that phosphorylation 
by Akt is needed for Mdm2 (an oncoprotein) to be translocated into the nucleus to reduce 
p53 levels and transactivation.  The study establishes a novel mitogen-regulated pathway 
linking the PI-3K/Akt and Mdm2/p53.  Furthermore, Tang and co-workers (2001) 
demonstrated that overexpression of a dominant negative Akt mutant suppress UVB-
mediated induction of Cox-2 promoter, implying a role of Akt in the UVB-induction of 
Cox-2 expression.   
 
1.2.2.7 P53 
UV radiation induces a high level of the tumor suppressor gene p53 expression in 
normal human skin (Healy et al., 1994; Hall et al., 1993; Campbell et al., 1993a).  In 
dividing cells, p53 is expressed at very low levels but is up-regulated in response to DNA 
damage.  Up-regulation of p53 levels results in growth arrest probably via induction of 
the cyclin-dependent kinase inhibitor p21Waf1/Cip1, followed by DNA repair, or apoptosis.  
Mutation of p53 by UV radiation would prevent G1 arrest and the initiation of apoptosis 
pathway and hence favor the continue division of mutant cells and the accumulation of 
additional mutations.  Brash and co-workers (1991) demonstrated C→T and CC→TT 
transitions in the p53 gene in 58% of human squamous cell carcinoma.  Since then, other 
researchers have detected p53 mutations in human basal cell carcinoma and actinic 
 24
keratoses (Ziegler et al., 1993; Rady et al., 1992; Moles et al., 1993; Nataraj et al., 1995).  
In animal studies, p53 mutations have been found in 20-100% of mouse skin cancers.  
The frequency of p53 mutations differ among mouse strains (Kress et al., 1992; Kanjilal 
et al., 1993), with CC→TT transition at dipyrimidine sites being the most detected 
mutation spot.  Generally, mutations in p53 in UV-induced skin cancers appear to have 
an early onset (Campbell et al., 1993b; Nakazawa et al., 1994).  In addition, UV 
signature p53 mutations were found in 60% of actinic keratoses (Hall et al., 1993), an 
early stage of SCC.  Recently, Jiang and colleagues (1999) showed that p53 knockout 
mice possess higher susceptibility to UVB-induced skin cancer, but these mice fail to 
develop spontaneous skin cancers.  The results suggested that p53 plays a major role in 
the response of keratinocytes to UV-induced DNA damage and a less prominent role in 
the control of normal proliferation of skin tissue. 
 One of the many mechanisms that regulate p53 activity is phosphorylation at 
multiple sites on the N-terminal activation domain (amino acid 1-42) by several different 
protein kinases both in vivo and in vitro (Meek, 1998; Giaccia and Kastan, 1998).  Recent 
studies showed that phosphorylation of p53 protein at serine 15 may play a critical role in 
the stabilization, up-regulation, and functional activation of p53 during cellular stress 
(Shieh et al., 1997; Siliciano et al., 1997; Unger et al., 1999; Lambert et al., 1998).  Shieh 
and coworkers (1997) demonstrated that the phosphorylation of serine 15 in vitro by 
DNA-dependent protein kinase (DNA-PK) leads to reduced binding to its negative 
regulator, the oncoprotein murine double minute 2 (MDM2).  This will lead to the release 
of p53 from the p53-MDM2 complex and stabilize p53 by preventing proteosome-
mediated p53 degradation.  Recently, ERKs and p38 of the MAP kinase family has been 
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demonstrated to phosphorylate p53 protein at serine 15 in response to UV irradiation 
(She et al., 2000).  In addition to serine 15, serine 20 and threonine 18 phosphorylation 
have been shown to weaken the interaction of p53 and MDM2 in vitro (Bottger et al., 
1999; Unger et al., 1999).   
 In addition to the N-terminal phosphorylation, modification also occurs at the C-
terminal.  It has been reported that serines 376 and 378 are normally phosphorylated in 
unstimulated cells and ionizing radiation (IR) induces rapid dephosphorylation of serine 
376 (Waterman et al., 1998).  The change will open up a binding site to which protein 14-
3-3 can bind, leading to stimulation of the site-specific DNA binding function of p53.  
p53 is also acetylated at C-terminal lysine residues 320 by transcription factor PCAF and 
at 373 and 382 by another transcription factor p300/CBP in response to IR and UV (Gu 
and Roeder, 1997; Liu et al., 1999; Sakaguchi et al., 1998).   
 
1.3 Apoptosis and carcinogenesis 
1.3.1 General introduction 
Apoptosis, or programmed cell death, was first introduced by Kerr and colleagues 
(1972) to describe a highly regulated and conserved cell death process in eukaryotic cells 
which is morphologically and biochemically distinct from necrotic cell death.  Generally, 
the process of apoptosis can be divided into 3 distinct phases: (1) Initiation phase, which 
involves the activation of the central molecular machinery initiated by pro-apoptotic 
stimuli; (2) Effector phase, which signals the committed cells undergoing a complete 
activation of the apoptotic machinery; (3) Degradation phase, which is characterized by 
the morphological and biochemical changes associated with apoptosis (Sanfilippo and 
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Blaho, 2003).  The morphological changes of apoptosis include cell shrinkage associated 
with loss of intracellular fluid and ions, plasma and nuclear membrane blebbing, 
chromatin condensation and DNA fragmentation, and the formation of apoptotic bodies 
(Kerr et al., 1972; Wyllie et al., 1980; Schwartzman and Cidlowski, 1993).  Apoptotic 
bodies are removed through phagocytosis by macrophages before plasma membrane 
integrity is lost (Savill et al., 1993).  Normally, the signal for apoptotic body’s clearance 
is triggered by the “flipping” of phosphatidylserine from the inner to the outer surface of 
the plasma membrane (Fadok et al., 1992).  The rapid clearance of apoptotic cells thus 
does not induce inflammatory response or tissue scarring in vivo. 
It is generally believed that apoptosis is a genetically controlled active cell death 
process to eliminate unwanted or potentially harmful cells during development and tissue 
homeostasis (Hengartner, 2000).  The machinery of apoptosis is highly conserved 
throughout revolution with many similarities between invertebrates and humans.  It has 
been shown that apoptosis can be induced in many cell types by various physiological or 
biochemical stimuli, including hormones, toxins, chemotherapeutic agents, carcinogens, 
ionizing radiation, growth factor withdrawal and physical trauma (McConkey, 1998).  
Abnormalities in the apoptotic process can result in serious pathological conditions such 
as cancer (Bursch et al., 1992), acute diseases (infarction, ischemia-reperfusion damage, 
septic shock, etc.) (Decaudin et al., 1998), some auto-immune diseases (Tan, 1994), 
acquired immunodeficiency syndrome (AIDS) (Ameisen et al., 1995) and 
neurodegenerative diseases (Alzheimer’s disease) (Raff et al., 1993).  Therefore, a good 
understanding of the molecular processes regulating apoptosis will greatly assist in 
developing therapies for apoptosis-related diseases.   
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 1.3.2 Mechanisms 
Apoptosis is a genetically encoded process to removed unwanted cells during 
development and tissue homeostasis.  Even though the mammalian signal transduction 
pathways affecting apoptosis is complex, substantial progress has been made in recent 
years to better define the nature and detail signaling pathways involved in this process.  
Indeed, the identities and precise substrate specificities of the “central executioner” in 
apoptosis, a large family of cysteine proteases or caspases, have been defined (Nicholson 
and Thornberry, 1997; Nicholson, 1999).  In addition, a prominent role for mitochondria 
in apoptosis has also emerged as a critical pathway during the execution phase of 
apoptosis.  It has been shown that mitochondria can trigger apoptosis by release of 
cytochrome c from intermembrane space to the cytosol (Li et al., 1997).  Furthermore, 
several protein families specifically involved in the molecular mechanism of apoptosis 
have been investigated, which include Bcl-2 and p53 (Fraser and Evan, 1996; Steller, 
1995).  Below is a brief description of the two major modulators identified in apoptosis, 
namely caspases and mitochondria.   
 
1.3.2.1 Caspases 
Genetic analyses in the nematode worm C elegans have identified two genes 
required for apoptosis in the developmental stage, namely ced-3 and ced-4, and one that 
inhibits apoptosis, ced-9 (Ellis et al., 1991).  The first human homologue of ced-3 being 
identified was the interleukine-1β-converting enzyme (ICE) (Yuan et al., 1993).  Many 
subsequent studies have revealed a large family of related protease that share the property 
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of being cysteine protease with specificity for cleaving substrates on the carboxyl side of 
aspartate residues (Alnemri et al., 1996).  Thus, the generic term “caspase” (c-asp-ase) 
was adopted and the individual caspases are numbered based on their chronological order 
of discovery.  Thus far, there are at least 14 discrete caspases have been identified in 
mammals (Sanfilippo and Blaho, 2003). 
Two major pathways of caspase activation induced by pro-apoptotic stimuli have 
been characterized (Sanfilippo and Blaho, 2003).  The first pathway is initiated by the 
extracellular binding of a death ligand to its receptor on the cell surface such as 
Fas/CD95 and TNFR1 (extrinsic pathway).  The activated receptor complex then serves 
as the docking site for other adaptor proteins to recruit the initiator caspase-8 and 10, 
which then activate effector caspase-3.  The second pathway integrates and intracellular 
apoptotic signal via a mitochondrial route (intrinsic pathway).  It was demonstrated that 
cytochrome c, the electron transport chain intermediate, was released from the 
mitochondria at an early stage in apoptosis (Li et al., 1997).  Once released, cytochrome c 
directly binds to apoptosis protease activating factor-1 (Apaf-1) in a dATP-dependent 
manner and promotes a conformational change that allows caspase-9 to join the complex 
termed “apoptosome” (Li et al., 1997).  This binding results in the enzymatic activation 
of caspase-9, which then activate a set of effector caspases such as caspase-3, 6 and 7 
(Cohen, 1997).    
Although caspases have been shown to play a major role in apoptosis in various 
experimental systems, there are reports that show cells can also undergo caspase-
independent cell death.  Examples of this caspase-independent cell death can be found in 
glucocorticoid-induced death of thymocytes (Hirsch et al., 1997), death of 
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haematopoietic cell lines induced by growth factor withdrawal (Ohta et al., 1997), death 
of target cells of cytotoxic T cells (Sarin et al., 1997), cell death induced by the second 
messenger ceramide (De Maria et al., 1997), or the enforced expression of Bax (Xiang et 
al., 1996), Bak and c-Myc (McCarthy et al., 1997).  Therefore, these observations argue 
that an alternative mechanism is able to mediate cell death in caspase-independent 
manner, possibly through activations of other protease such as serine protease, calpains 
and cathepsins (Borner and Monney, 1999).  Further studies are needed to provide a 
better understanding for this distinct mechanism of apoptosis. 
 
1.3.2.2 The mitochondria 
It is well established that mitochondrial alterations have a major impact on 
apoptosis.  Several independent lines of evidence have highlighted the involvement of 
mitochondria in apoptosis.  First of all, kinetic data indicate that mitochondria undergo 
major changes in membrane integrity before the onset of classical signs of apoptosis.  
Generally, a disruption of mitochondria membrane potential (MMP) is detected early in 
the apoptosis process, well before all the major changes in cell morphology and 
biochemistry that include nuclear DNA fragmentation and the exposure of 
phosphotidylserine on the outer surface of plasma membrane (Susin et al., 1998).  
Furthermore, some profound structural and functional changes in mitochondria also occur 
during apoptosis, leading to the release of intermembrane proteins such as cytochrome c 
and apoptosis inducing factor (AIF) (Liu et al., 1996; Susin et al., 1996; Kluck et al., 
1997).    These mitochondria products are capable of mediating the activation of caspases 
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and endonucleases that cause isolated nuclei to undergo apoptosis in cell free system 
(Zamzami et al., 1996; Susin et al., 1996).   
In addition, functional and pharmacological studies propose that mitochondria 
permeability transition (MPT) induced by the permeability transition (MT) pore opening 
is one of the key mediators of apoptosis.  Upon activation by pro-apoptotic stimuli, a 
large nonselective conductance channel composed of both inner and outer membrane 
proteins is opened (Green and Reed, 1998). This MT pore allows ions of the matrix and 
intermembrane space to equilibrate and causes the mitochondrial inner transmembrane 
potential (ΔΨ2m) to collapse by dispelling the H+ gradient (Petit et al., 1995; Qian et al., 
1997) .Opening of the PT pore also induces volume expansion of the matrix, eventually 
leading to the rupture of the outer membrane and the release of caspase activators such as 
cytochrome c, Smac/DIABLO, AIF, and EndoG nuclease into the cytosol (Green and 
Evan, 2002).  Moreover, the importance of MPT in apoptosis is further strengthened by 
the fact that pharmacological inhibitors of MPT such as cyclosporine A and Bongkreikic 
acid are capable of preventing the loss of MMP and thus blocking apoptosis (Zamzami et 
al., 1995; 1996). 
Once released into the cytosol, cytochrome c directly binds to apoptosis protease 
activating factor-1 (Apaf-1) in a dATP-dependent manner and leads to its oligomerization 
(Zou et al., 1997).   This conformational change allows caspase-9 to join and forms a 
complex termed “apoptosome” and results in the enzymatic activation of caspase-9, 
which then activate a set of effector caspases such as caspase-3, 6 and 7 (Cohen, 1997).   
Downstream effector caspase activations can be prevented by a family of endogenous 
caspase inhibitors termed inhibitors of apoptosis proteins (IAPs).  These cytosolic IAPs 
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are capable of direct binding and inhibiting the active caspase-9 as well as targeting 
active caspases for degradation (Suzuki et al., 2001).  On the other hand, an 
intermembrane space protein called Smac/DIABLO has been shown to disable IAPs and 
assist in caspase-9 activation (Du et al., 2000; Verhager and Vaux, 2002).  Additionally, 
AIF promotes apoptosis by inducing chromatin condensation (Susin et al., 1996) while 
EndoG exerts its pro-apoptotic effect by mediating DNA fragmentation (Li et al., 2001). 
Finally, extensive studies have proven members of the Bcl-2 family proteins can 
regulate the mitochondrial apoptotic pathway (Green and Evan, 2002; Cory et al., 2003; 
Chao and Korsmeyer, 1998).  All members of Bcl-2 proteins possess at least one of four 
conserved motifs known as Bcl-2 homology domains (BH1 to BH4), and many of these 
proteins also have a conserved C-terminal transmembrane region that anchors them to the 
cytosolic side of the outer mitochondrial membrane (Krajewski et al., 1993).  Generally, 
these proteins can be classified into 3 categories: (1) anti-apoptotic, which include Bcl-2, 
Bcl-XL, Bcl-w and Mcl-1; (2) pro-apoptotic “BH123”, which share 3 of the BH domains 
with their anti-apoptotic counterparts, and include Bax, Bcl-XS, Bak and Bok; and (3) 
pro-apoptotic “BH3 only” proteins, which contain only a BH3 domain, and include Bad, 
Bid, Bik, Bim and Bmf (Sanfilippo and Blaho, 2002).  The exact mechanisms by which 
Bcl-2 family members exhibit their effects are varied.  For instance, Bax has been shown 
to create pores and can insert into the outer mitochondrial membrane to allow the passage 
of caspase-activating factors into the cytosol (Martinou and Green, 2001).  Furthermore, 
Bcl-2 and Bcl-XL can bind to Apaf-1 and inhibit its association with pro-caspase-9, while 
the pro-apoptotic Bik may free Apaf-1 from these inhibitions (Pan et al., 1998; Hu et al., 
1998; Chinnaiyan et al., 1997; Chaudhary et al., 1999).   On the other hand, the BH-3 
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only Bid can be cleaved by activated caspases to a truncated form (tBid) that inserts into 
the mitochondrial membrane and promotes the release of caspase-activating factors (Zha 
et al., 2000; Gross et al., 1998; Li et al., 1998; Luo et al., 1998).  
 
1.3.3 Implications of apoptosis in cancer and some therapeutic approaches 
Apoptosis is an essential cell death process in maintaining development and tissue 
homeostasis.  Each day, millions of cells undergo apoptosis in order to secure the 
functionality of the whole organism.  Thus, it is not surprising that any defects in this 
important process can result in severe pathological diseases of which one of the most 
important is cancer (Fisher and Schulze-Osthoff, 2005).  Dysregulation of apoptosis has 
also been shown to be crucial in the pathogenesis of cancer by: (1) allowing neoplastic 
cells to survive beyond their normal lifespan; (2) creating a permissive environment for 
genetic instability and accumulation of gene mutations; (3) facilitating growth factor- and 
hormone-independent cell survival; (4) promoting resistance to immune-based 
destruction; and (5) conferring resistance to cytotoxic anticancer agents and radiation 
(Reed, 1999).  
Most of the key cellular members regulating apoptosis have been identified in 
recent years and can be targeted by therapeutic approaches, which include the death 
receptors, Bcl-2 proteins, tumor suppressor p53, inhibitor of apoptosis (IAP), etc.  A 
major pathway of apoptosis is mediated by cellular death receptors from tumor necrosis 
factor (TNF) receptor family.  Even though ligands of the death receptors can efficiently 
induce cell death in a variety of tumor cells, severe toxicity was observed in mice and 
human (Daniel et al., 2001).  Recently, the discovery of TNF-related apoptosis-inducing 
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ligand (TRAIL) has raised new hope in therapeutic approaches that target death receptors.  
TRAIL has been shown to specifically eliminate tumor cells while normal cells are not 
affected.  Pre-clinical safety studies in primates demonstrated no toxicity of TRAIL 
treatment (Walczak et al., 1999).  Furthermore, it is believed that apoptosis-resistance 
tumors usually contain mutation in tumor suppressor p53 or overexpression of the anti-
apoptotic Bcl-2 family members.  TRAIL-induce apoptosis is independent of p53 or 
overexpression of Bcl-2 family proteins and thus able to overcome the resistance.  Indeed, 
combinations treatments of TRAIL with conventional chemotherapeutic agents or 
ionizing radiation vastly enhance their therapeutic effect (Held and Schulze-Osthoff, 
2001). 
Members of the Bcl-2 family play an essential role in the intrinsic mitochondrial 
pathway, with either pro- or anti-apoptotic functions.  Diverse strategies have been 
applied to target Bcl-2, Bcl-XL and Mcl-1 in cancer therapy.  One approach is to 
modulate Bcl-2 by antisense techniques to downregulate the protein.  It was found that an 
antisense Bcl-2 construct could effectively induce apoptosis by itself or in combination 
with standard chemotherapeutic agents in lymphoma and leukemia cells (Campos et al., 
1994; Keith et al., 1995).  Another approach is to apply BH3 domain peptides to bind to 
and disrupt Bcl-2 like protein complex and thus sensitizing cells to apoptosis.  Indeed, a 
BH3 peptide has been shown to sensitize Bcl-XL overexpressing cells to CD-95-mediated 
apoptosis (Holinger et al., 1999).  Furthermore, several small-molecule drugs interfering 
with Bcl-2/Bcl-XL function have been reported.  For instance, an antibiotic from 
Actinomyces, Tetrocarcin A, was found to sensitize Bcl-2 overexpressing HeLa cells to 
death receptor and drug-mediated apoptosis (Nakashima et al., 2000).  Antimycin A3, an 
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inhibitor of the mitochondrial electron transport chain, has also been demonstrated to 
induce cell death in Bcl-2 and Bcl-XL overexpressing cells (Tzung et al., 2001). 
In the past decade, substantial research have been conducted to target tumor 
suppressor gene p53 in cancer therapy due to the fact that inactivation of p53 is reported 
in more than 50% of human cancers (Wallace-Brodeur and Lowe, 1999).  A promising 
approach is to restore the transcriptional activity of mutant p53 by introducing a small 
peptide to either stabilize p53 (Selivanova et al., 1997; 1999) or interfere with the binding 
of its negative regulator Mdm2 (Chene et al., 2000; Stoll et al., 2001; Vassilev et al., 
2004).  In addition, targeting heat shock protein (Hsp)-90 by geldanamycin has been 
reported to deplete mutant p53 by restoring the degradation of mutant p53 by proteasome 
in various tumor cell lines (Blagosklonny et al., 1995; An et al., 1997).  On the other 
hand, inhibition of p-53 mediated transcription and apoptosis in normal tissues has been 
shown to relieve the genotoxic stress associated with chemo- and radiotherapy treatments.  
In fact, a p53 inhibitor, pifithrin-α, completely rescued mice from doses of radiation that 
normally killed 60% of the mice (Komarov et al., 1999).  
Inhibitors of apoptosis (IAPs) comprise a family of caspase-inhibiting proteins 
characterized by a shared conserved baculovira IAP repeat (BIR) domain (Salvesen and 
Duckett, 2002).  In addition to their well-established caspase-inhibiting capability, 
growing evidence also suggests the role of IAPs in other cellular functions such as 
protein degradation, cell cycle control and signal transduction (Deveraux and Reed, 
1999).  Many studies have explored the possibility of targeting IAPs in cancer therapy 
with promising results accumulated through the years.  For example, antisense targeting 
XIAP has been shown to sensitize many tumor cell types to radio- or chemotherapy 
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(Valentino et al., 2003; Sasaki et al., 2000).  Furthermore, XIAP antisense therapy 
combined with vinorelbine are also effective in mouse xenograft model of lung cancer 
(Hu et al., 2003).  Recently, one such antisense oligonucleotide, AEG35156, has been 
shown to have high efficacy in multiple cancer models and has just entered phase I 
clinical trial (Fischer and Schulze-Osthoff, 2005). 
In summary, rapid advances in the understanding of apoptosis regulation and in-
depth mechanisms of action have laid a solid foundation for more exciting drugs 
targeting apoptosis. 
 
1.4 Objectives of the study 
At present, there is some preliminary evidence showing the anticancer property of 
PN.  However, this property of PN has not been studied in any animal model, and the 
exact mechanism(s) by which PN exhibits its anticancer activity has not been fully 
elucidated.  Thus, the main objectives of the present study are:  
(1) To investigate the chemopreventive and chemotherapeutic potentials of PN 
against UVB-induced skin cancer in SKH-1 hairless mice 
(2) To explore the molecular mechanism(s) involved in the anticancer effect of PN in 
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Traditionally, feverfew (Tanacetum parthenium) is used as a herbal medicine for 
the treatment of fever, arthritis, and migraine in Europe.  The crude extracts of this herb 
is known to have anti-microbial and anti-inflammatory properties (Brown et al., 1997; 
Jain et al., 1999).  The principal active component in feverfew is the sesquiterpene 
lactone PN that contains a highly electrophilic α-methylene-γ-lactone ring and an epoxide 
residue capable of interacting rapidly with nucleophillic sites of biological molecules 
(Macias et al., 1999).  At present, there is some preliminary evidence showing the anti-
cancer property of PN.  For instance, PN is a potent inhibitor of DNA synthesis and cell 
proliferation in a number of cancer cell lines (Woynarowski and Konopa, 1981; Hall et 
al., 1988; Ross et al., 1999).  Recently, Wen and colleagues (2002) demonstrated that 
PN-induced apoptosis involves caspase activation and mitochondria dysfunction in 
hepatoma cells.  To date, the anti-cancer property of PN has not been studied using in 
vivo animal models. 
Skin cancer is the most common type of cancer among Caucasians (Parker et al., 
1997).  Clinically, skin cancers are classified into two major groups: malignant melanoma 
(MM) and non-melanoma skin cancer (NMSC).  Ultraviolet radiation (UV) wavelength 
range borders at the violet end of the visible light range at 400 nm.  Wavelength ranges in 
the region of 400-320 nm is classified as UVA, while UVB ranges from 320-280 nm, and 
UVC ranges from 280-200 nm.  Numerous studies have demonstrated UVB as the major 
etiological factor for NMSC (Jung, 1991; Brash, 1997; Yamawaki et al., 1997), which is 
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derived from skin epithelial cells and can be further categorized into squamous cell 
carcinoma (SCC) and basal cell carcinomas (BCC) (de Grujil, 1999).   
 In this study, we investigated the anti-cancer property of PN using UVB-induced 
skin cancer model in SKH-1 hairless mice.  As a positive control, we applied celecoxib, a 
specific COX-2 inhibitor with proven chemopreventive activity against skin cancer in a 
similar model (Fischer et al., 1999; Pentland et al., 1999).  Our results demonstrated for 
the first time PN possesses strong cancer chemopreventive property in an animal model. 
 
2.2 Materials and Methods 
2.2.1 Chemicals and Animals 
 PN (97% pure) was purchased from Biomol (Plymouth Meeting, PA).  Celecoxib 
was kindly provided by Pfizer (New York, NY).  SKH-1 hairless mice were purchased 
from Charles River Laboratories (Wilmington, MA), and they were at 8-9 weeks of age at 
the beginning of the experiments.  Animals were maintained at the Animal Holding Unit, 
NUS and all experimental protocols were approved by the University Animal Welfare 
Committee. All mice were housed in the Animal Holding Unit under climate-controlled 
environment with a 12-hour light/dark cycle. Mice were allowed free access to food 
pellets and water. 
 
2.2.2 Apparatus for UVB exposure 
UVB was delivered through a bank of FS24 lamps (Light Sources Inc., Orange, 
CT) with spectral irradiance of 280-400 nm, 80% of which in the UVB region (280-320 
nm) and with a peak at around 313 nm.  These UVB lamps were incorporated into a light 
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therapy unit similar to those in many local hospitals for the treatment of jaundice in 
infants (Figure 2.1a).  The emitted UVB dose was quantified using a phototherapy 
radiometer (International Light, Newburyport, MA) equipped with IL SED 240 detector.   
 
2.2.3 Preparation of the special food diet 
Both compounds were first dissolved in DMSO, diluted with sunflower oil, and 
then coated onto food pellets.  Food pellets were purchased from Glen Forrest Stock 
Feeders (Western Australia, Australia), with a fixed formula ratio using wheat, lupins, 
barley, soya meal, fish meal, mixed vegetable oils, canola oil, salt, calcium carbonate, 
dicalcium phosphate, magnesium oxide, and a vitamin and trace mineral premix.  The 
calculated nutritional parameters are approximately 19% proteins, 4.6% total fat, and 
4.5% crude fiber.  Once coated, these food pellets were stored at 4°C.  Fresh food pellets 
were supplied 3 times a week and the amount of consumption was recorded at the same 
time.  The dosage of celecoxib is based on a published study (Fisher et al., 1999) where 
500 ppm of celecoxib had been shown to possess strong chemopreventive activity against 
UVB-induced skin cancer.   
 
2.2.4 Determination of PN content in the prepared food pellets 
To examine the stability of PN in the food pellets used in this study, the 
concentrations of PN in special prepared food pellets stored at 4 °C for 1, 3 and 7 days 
were determined using mass spectrometry.  Briefly, each pellet was grinded into powder 
before being soaked with pure ethanol overnight.   The subsequent solvents containing 
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PN were then subjected to MS.  The mass spectra were monitored on a LCQ mass 
spectrometer equipped with an APCI interface (Finnigan LCQ Duo, Bremen, Germany).   
 
2.2.5 Establishment of the UVB-induced skin cancer animal model 
 The in vivo model is based on a published method (Fisher et al., 1999; Pentland et 
al., 1999) with modifications, which includes the following procedures.   
 
2.2.5.1 Determination of Minimal Erythema Dose (MED) 
 In order to establish the UVB dosage used in the current study, a short experiment 
to determine the minimal dose of UVB that induce erythema response (redness skin) in 
female SKH-1 hairless mice was conducted.  Mice were divided into 6 groups (5/group) 
which received 0, 50, 100, 200, 300, 400, or 500 mJ/cm2 of UVB.  Erythema response 
was then examined 24 hours after UVB exposure.  The result showed that 200 mJ/cm2 
was the MED in this study.   
 
2.2.5.2 Induction of skin cancer by UVB 
Mice were placed in a box partitioned to 6 separate compartments (Figure 2.1b) 
and exposed to an initial dose of 100 mJ/cm2 of UVB (5 days/week).  A weekly 
increment of 50 mJ/cm2 was applied until a maximal dose of 200 mJ/cm2 was reached.  
The UVB treatment was continued for 25 weeks.  A negative control group (no PN 
treatment and no UVB exposure, n=5) was included throughout the study.  Papilloma 
(lesion >1 mm) were examined and recorded weekly.  Papilloma incidence (% of mice 
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with one or more papilloma) and papilloma multiplicity (# of papilloma/mouse) were 
determined after the termination of the UVB treatment.   
 
2.2.6 Treatment with PN 
2.2.6.1 Chemopreventive aspect 
Two different PN treatment schemes were designed, aiming to examine both the 
chemopreventive and the chemotherapeutical value of PN against UVB-induced skin 
cancer. The details of both UVB irradiation and PN and celecoxib treatment schemes 
were summarized in Figure 2.2.  In order to study the chemopreventive activity of PN, 
mice were fed with prepared food pellets containing DMSO, PN, or celecoxib one week 
prior to UVB exposure and throughout the study. 
 
2.2.6.2 Chemotherapeutic aspect 
Various treatments with PN and celecoxib and UVB irradiation schemes were 
summarized in Figure 2.3 to evaluate their chemotherapeutic value.  Mice were exposed 
to an initial dose of 100 mJ/cm2 of UVB (5 days/week).  A weekly increment of 50 
mJ/cm2 was applied until a maximal dose of 200 mJ/cm2 was reached.  The UVB 
treatment was continued for 14 weeks.  At that point, mice were given 2% DMSO, 3 
mg/day or 5 mg/day PN, or 3 mg/day celecoxib mixed in the food pellets (as described 
above).  The drug treatments lasted for 14 weeks, while body weight and papilloma 
number were recorded concurrently.  Papilloma incidence (% of mice with 1 or more 
papilloma) and papilloma multiplicity (# of papilloma/surviving mice) were determined 







Figure 2.1 UVB exposure setup (a) UVB exposure unit with 8 UVB lamps. (b) 
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  Figure 2.2 Schematic representation of the chemopreventive aspect of PN or 
celecoxib against UVB-induced skin cancer in SKH-1 hairless mice.  
Mice were placed on diet containing 2% DMSO (group 1), 1 mg/day 
PN (group 2), 3 mg/day celecoxib (group 3) 1 week prior to the 
initiation of UVB exposure and was maintained throughout the study.  
Mice were exposed to an initial dose of 100 mJ/cm2 of UVB (5 
days/week), with an increment of 50 mJ/cm2 per week until a maximal 
dose of 200 mJ/cm2 was reached.  The UVB treatment was continued 
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Figure 2.3 Schematic representation of the chemotherapeutic aspect of PN or 
celecoxib against UVB-induced skin cancer in SKH-1 hairless mice.    
Mice were exposed to an initial dose of 100 mJ/cm2 of UVB (5 
days/week), with an increment of 50 mJ/cm2 per week until a maximal 
dose of 200 mJ/cm2 was reached.  The UVB treatment was continued 
for 14 weeks.  Mice were then placed on diet containing 2% DMSO 
(group 1), 3 mg/day PN (group 2), 5 mg/day PN (group 3), or 3 




 2.2.7 Tissue collection 
All mice were humanly sacrificed at the end of the 25-week or 28-week study.  
Papillomas were surgically removed, paraffin embedded and cut into 4 μm sections in 
preparation for immunohistochemistry staining.  The dorsal skins of mice were also 
removed, snap-frozen in liquid nitrogen, and then stored at -80˚C until further analysis. 
 
2.2.8   Immunohistochemical analysis of COX-2 
All tissue sections (4 µm) fixed on microscopic slides were dewaxed via the 
following sequence:  
1) 10 mins in xylene 
2) 10 min in xylene 
3) 5 min in 100% ethanol 
4) 5 min in 100% ethanol 
5) 5 min in 90% ethanol 
6) 5 min in 70% ethanol 
7) 5 min in tap water 
All tissue sections were incubated in 3% hydrogen peroxide for 5 min before 
washing with PBS twice.  Then, tissue sections were incubated in working solution of Ig 
blocking reagent from VECTOR® M.O.M. immunodetection kit (Vector Laboratories, 
Burlingame, CA) for 1 hour.  After washing with PBS twice, sections were incubated 
with working solution of MOM diluent for 5 min and proceed to incubation with anti-
Cox-2 primary monoclonal antibody (Transduction Laboratories, Los Angeles, CA) for 1 
hour at 37 °C.  After washing with PBS twice, the MOM biotinylated anti-mouse IgG 
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reagent was applied to the tissue sections for 10 min, follow by 5 min incubation with 
Vectastain ABC reagent.  Sections were then incubated with 3,3’-diaminobenzidine 
(DAB) substrate for 10 min.  Slides were counterstained with hematoxylin-1 (Sigma-
Aldrich, St Louis, MO) for 15 seconds.  Finally, sections were dehydrated via the 
following sequence, mounted and covered with coverslips:  
1) 5 min in 70% ethanol 
2) 5 min in 90% ethanol 
3) 5 min in 100% ethanol 
4) 10 min in xylene 
5) 10 min in xylene 
 
2.2.9   PGE2 level determination in murine skin samples 
Skin samples in phosphate buffer (0.1 M, pH7.4, 1 mM EDTA, 10 µM 
indomethacin) were homogenized on ice for 1 min at 20,000 rpm.  Equal volume of 
100% ethanol was added to the homogenates, vortexed, and the mixtures were left at RT 
for 5 min.  The mixtures were centrifuged at 3,000 g for 10 min at 4 °C, and the 
supernatants were transferred to other tubes and further diluted with 50 mM citrate buffer 
(pH4.0) until the ethanol concentration is below 15%.  The samples were purified using a 
Sep-Pak® Vac C-18 cartridge (Waters, Milford, MA).  PGE2 in skin samples were 
measured using monoclonal enzyme immunoassay kit (Cayman, Ann Arbor, MI) 




2.2.10 Statistical analysis 
All numeric data are presented as means ± standard deviations (SD) and analyzed 
using one-way ANOVA with Student-Newman-Keuls multiple comparisons as post-hoc 
test (SPSS 11.5).  Part of the results from the animal study was analyzed using Fisher 
exact probability test.  A P value < 0.05 is considered as statistical significance. 
 
2.3 Results 
2.3.1 Chemopreventive property of PN against UVB-induced skin cancer in SKH-1 
hairless mice 
In this study, the anti-cancer property of PN was first tested in a UVB-induced 
mouse skin cancer model which was established based on published methods (Fischer et 
al., 1999; Pentland et al., 1999).  It is noted that the special prepared food diet achieved a 
constant delivery of PN to the mice as shown in Figure 2.4.  No papilloma was detected 
in the negative control group throughout the study.  As shown in Figure 2.5, PN (1 
mg/mouse/day) or celecoxib (3 mg/mouse/day) significantly delayed the onset of 
papilloma incidence comparing to the UVB-only group: the UVB-only group reached 
100% tumor incidence at week 13th, while PN- or celecoxib- fed groups achieved full 
tumor incidence at week 18th and 20th, respectively.  Papilloma yield (number of 
papilloma/mouse) was also significantly reduced in mice fed with either PN or celecoxib 

























Figure 2.4 The concentrations of PN in special prepared food pellets as determined by 
mass spectrometry.  PN was first dissolved in DMSO, diluted in sunflower oil, 
and then coated onto each pellet.  These pellets were stored at 4 °C for 1, 3 or 
7 days.  Each pellet was grinded into powder form before being soaked with 
pure ethanol overnight.   The subsequent solvents containing PN were then 
subjected to MS.  Data were presented in means ± standard deviations from 
three independent experiments and analyzed using one-way ANOVA with 
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Figure 2.5 Inhibitory effects of PN and celecoxib on UVB-induced papilloma 
incidence in SKH-1 hairless mice.  Mice were placed on diet 
containing PN or celecoxib (n=10) 1 week prior to the beginning of 
UVB irradiation (5 times/week) and the number of papillomas were 
counted weekly.  Papilloma incidence was calculated as the percentage 
of mice having tumors in each treatment group and analyzed using 
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Figure 2.6 Inhibitory effects of PN and celecoxib on UVB-induced papilloma 
yield in SKH-1 hairless mice.  Mice were placed on diet containing PN 
or celecoxib (n=10) 1 week prior to the beginning of UVB irradiation (5 
times/week) and the number of papillomas were counted weekly.  
Papilloma yield was calculated as the mean values of papillomas/mouse 
± SD for each treatment group, and analyzed using one-way ANOVA 
with Student-Newman-Keuls multiple comparisons test on data from the 
last three weeks of the study.  Asterisks indicate significant difference 




that of celecoxib (40%).  In addition, differences in the severity of tumor growth (Figure 
2.7) and the size distribution of papilloma among different groups were also noted (Table 
2.1): papillomas observed in the group fed with PN were of smaller size (73% papillomas 
of 1-2 mm in diameter) as compared to that of the control (59%).  Furthermore, 
immunohistochemical staining (Figure 2.8) showed both PN and celecoxib treatments 
markedly inhibited the UVB-induced hyperplastic response (increased thickness of the 
epidermis) as compared to the control group.  The effect of celecoxib is more profound, 
and this observation is basically consistent with the data in Figure 2.5 and 2.6.  Taken 
together, here for the first time strong evidence from this study shows that PN possesses 
strong chemopreventive property against UVB-induced skin cancer. 
 
2.3.2    Effect of PN on UVB-induced COX-2 activity in murine skin 
It has been well known that COX-2 over-expression is implicated in UVB-
induced skin cancer (Buckman et al., 1998; Chan et al., 1999; Athar et al., 2001), and 
COX-2 inhibitors are known to be effective in preventing UVB-induced skin cancer 
(Fischer et al., 1999; Pentland et al., 1999).  Surprisingly, in the present study COX-2 is 
unlikely to be the direct molecular target of either PN or celecoxib.  As shown in Figure 
2.9, UVB exposure led to COX-2 over-expression in skin tissue determined by 
immunohistochemistry, while either PN or celecoxib failed to suppress this reaction 
(Figure 2.9).  A consistent pattern of changes was also found for the PGE2 level in the 
skin tissue: UVB exposure markedly enhanced the PGE2 level, while no reduction was 








Figure 2.7 Tumor growth in UVB-treated mice fed with diet containing (B) 
DMSO, (C) 1 mg/day PN and (D) 3 mg/day celecoxib.  A negative 
control group on normal diet with no UVB exposure was also included 
(A).  Mice were placed on these diet one week prior to and were 
continued throughout the 25 weeks of UVB exposure (5 times/week).  







Table 2.1 Size distribution of papillomas 
Treatment Group n % small papillomas (1-2 mm)# % big papillomas (≥ 3 mm) 
Control (UVB only)  10 59.00 ± 10.52 41.0 ± 9.32 
PN + UVB 10 73.67 ± 6.54* 26.33 ± 5.34* 
Celecoxib + UVB 10 65.90 ± 6.15 34.10 ± 11.1 
 
# Means ± SD   
* P<0.05 comparing to the UVB-only control group using one-way ANOVA with 


















Figure 2.8 Effects of PN and celecoxib on UVB-induced hyperplasia (area 
between the arrows).  Mice were placed on diet containing (B) DMSO, 
(C) 1 mg/day PN and (D) 3 mg/day celecoxib.  A negative control 
group on normal diet with no UVB exposure was also included (A).  
Mice were placed on these diet one week prior to and were continued 
throughout the 25 weeks of UVB exposure (5 times/week).  At the end 
of the study, dorsal skins of the mice were removed and formalin fixed.  
Cut sections (4µm) were processed for hematoxylin and eosin staining, 







Figure 2.9 Immunohistochemistry staining of COX-2 in mouse skin samples.  
Skin samples were stained for COX-2 at the end of the study protocol.  
Images of (A) negative control, (B) DMSO, (C) PN and (D) celecoxib-
treated groups were photomicrographed at 1000x.  COX-2 protein was 






















+ UVB irradiation 
 
 
Figure 2.10 PGE2 levels in untreated or UVB-irradiated mice fed with DMSO-, 
PN- or celecoxib-containing diets.  PGE2 was extracted from the skin 
samples at the end of the study protocol and analyzed by enzyme 
immunoassay described in materials and methods.  Data were 








the chemopreventive activity of PN or celecoxib might be independent of COX-2 in the 
present experimental system. 
 
2.3.3 Chemotherapeutic property of PN against UVB-induced skin cancer in SKH-1 
hairless mice 
Generally when one is diagnosed with cancer, all risk factors associated are 
advisedly avoided.  Thus, this account has been incorporated into the present 
experimental design: UVB exposure for 14 weeks to induce skin cancer, at which UVB 
exposure was stopped and the treatment initiated.  However, the results showed that PN is 
not an effective chemotherapeutic agent: Papilloma yield (number of papilloma/mouse) 
was not significantly different between in mice treated with DMSO control and either 
dosages of PN (3 or 5 mg/day) (Figure 2.11).  Differences in the severity of tumor growth 
(Figure 2.12) and the size distribution of papilloma among different groups were not 
detected (Table 2.2).  Thus, it is concluded that PN is not an effective single 
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Figure 2.11 PN has no effect on papilloma yield after 14 weeks of UVB exposure.   Mice 
were placed on diets containing (A) DMSO, (B) 3 mg/day PN (C) 5 mg/day 
PN, and (D) 3 mg/day celecoxib after 14 weeks of UVB exposure (5 
times/week) and the number of papillomas were counted weekly.  Papilloma 
yield was calculated as the mean values of papillomas/mouse ± SD for each 
treatment group, and analyzed using one-way ANOVA with student-







Figure 2.12 Tumor growth in UVB-treated mice fed with diet containing (A) 
DMSO, (B) 3 mg/day PN (C) 5 mg/day PN, and (D) 3 mg/day 
celecoxib.   Mice were placed on these diets after 14 weeks of UVB 
exposure (5 times/week) and continued for 14 weeks.  Pictures were 




Table 2.2 Size distribution of papillomas 
Treatment Group n % small papillomas (1-2 mm)# % big papillomas (≥ 3 mm) 
Control (UVB only)  8 68.12± 7.41 31.88 ± 7.97 
3 mg/day PN + UVB 8 65.08 ± 5.89 34.92 ± 7.59 
5 mg/day PN + UVB 8 58.93 ± 4.42 41.07± 11.01 
Celecoxib + UVB 6 80.95 ± 11.42 19.05 ± 10.41 




Previous studies have demonstrated PN as a potent inhibitor of DNA synthesis and 
cell proliferation in a number of cancer cell lines (Woynarowski and Konopa, 1981; Hall 
et al., 1988; Ross et al., 1999).  More recently, PN has been reported to be a potent 
apoptosis inducer in human cancer cells (Wen et al., 2002).  Furthermore, it has been 
shown that PN sensitizes breast cancer cells to chemotherapeutic agent paclitaxel (Patel  
et al., 2000).  However, the anti-cancer potential of PN has not been tested on animal 
models.  Here for the first time clear evidence has shown that PN possesses 
chemopreventive property against UVB-induced skin cancer in female SKH-1 hairless 
mice: 1) PN treatment delayed the onset of tumor incidence from week 13th to week 18th 
(Figure 2.5); 2) PN reduced tumor multiplicity by 30% (Figure 2.6); 3) smaller papilloma 
sizes were found in mice treated with PN (Table 2.1); and 4) PN treatment reduced the 
hyperplastic response of the epidermis induced by UVB irradiation (Figure 2.8).  The 
chemopreventive capability of PN is found to be as effective as the pharmaceutical COX-
2 inhibitor celecoxib in preventing UVB-induced photocarcinogenesis (Fischer et al., 
1999; Pentland et al., 1999).   
COX-2 is the inducible subtype of the enzyme cyclooxygenase (COX) which 
converts free arachidonic acid to prostaglandins (Marnett, 2000).  The fact that UVB 
upregulates COX-2 and prostaglandins production suggested COX-2 may contribute to 
photocarcinogenesis (Buckman et al., 1998; Grewe et al., 1993).  Preliminary findings 
from our laboratory revealed a positive correlation between cytotoxic response to PN and 
COX-2 expression (unpublished data), which leads us to hypothesize that PN may exert 
its effect in a COX-2-dependent manner.  However, the results showed that neither 
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treatment of PN nor the specific COX-2 inhibitor celecoxib alter COX-2 expression or 
prostaglandins production induced by UVB (Figure 2.9 and 2.10), suggesting that COX-2 
is unlikely to be the direct molecular target for PN and celecoxib.  This finding is in 
concordance with previous report in which long term oral treatment of celecoxib has no 
effect on UVB-induced expression of COX-2 (Fischer et al., 1999).  Furthermore, in vitro 
studies also demonstrated that celecoxib induces apoptosis and cell cycle arrest in a 
COX-2 independent manner (Elder et al., 1997; Grosch et al., 2001; Waskewich et al., 
2002).  In contrast, a recent study reported that topical treatment of celecoxib is as 
effective as oral route in inhibiting UVB-induced skin cancer while also suppressed PGE2 
production induced by UVB (Wilgus et al., 2003).  It remains to be determined whether 
such a difference in PGE2 suppression by celecoxib is due to the different routes of 
administration applied. 
Initially, several studies have been planned to identify the possible molecular targets 
responsible for the chemopreventive activity of PN against UVB-induced skin cancer by 
examining the changes in mRNA and protein expression levels of certain important 
proteins being implicated in UVB-induced skin cancer.  However, it was later found that 
the mRNA prepared from the murine skins was severely degraded when the qualities of 
RNA were tested by electrophoresis through agarose gels containing formaldehyde.  
Moreover, the qualities of proteins extracted from the same batch of murine skin samples 
were also questionable and thus not suited for further analysis.  Thus, further 
identifications for the possible molecular targets were unsuccessful.  In summary, strong 
evidence from this study has demonstrated the chemopreventive property of PN against 
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UVB-induced skin cancer in SKH-1 hairless mice.  The results also suggested that such 











PARTHENOLIDE SENSITIZES CELLS TO UVB-INDUCED 








 3.1 Introduction: 
The mechanism(s) of UVB-induced skin cancer have not been fully understood. 
Several transcriptional factors including activator protein-1 (AP-1), NF-κB, nuclear 
factor of activated T cells (NF-AT), and signal transducers and activators of transcription 
(STATs) have been linked to the tumor-promoting ability of UVB (Angel et al., 2001; 
Siebenlist et al., 1995; Huang et al., 2000; Zhang et al., 2001).  AP-1 is an important 
nuclear transcription factor involved in many cellular functions such as cell proliferation, 
cell death, cell survival and differentiation (Shaulian and Karin, 2002).  The mammalian 
AP-1 complex consists of either homodimers or heterodimers of Jun (c-Jun, JunB, JunD), 
Fos (c-Fos, FosB, Fra-1, Fra-2), Jun dimerization partners (JDP1 and JDP2), and the 
closely related activating transcription factors (ATF2, LRF1/ATF3 and B-ATF) (Karin et 
al., 1997).  Depend on the composite, the resulting AP-1 complex can then binds to and 
transactivates either the TPA-response element (TRE) or the cAMP responsive elements 
(CRE) to regulate the transcription of many genes involved in cell proliferation, apoptosis, 
metastasis, and cellular metabolism (Angel et al., 2001; Jochum et al., 2001; Ozanne et 
al., 2000).  One important aspect of AP-1 function is its role in tumor promotion based on 
the fact that viral and cellular Jun or Fos can cause malignant transformation in 
fibroblasts (Lamb et al., 1997; Suzuki et al., 1994).  Gene products promoting invasion 
and metastasis are also under AP-1 regulation (Lamb et al., 1997).  Furthermore, 
inhibition of UVB-induced skin cancer has been shown to be mediated through 
suppression of AP-1 transactivation (Barthelman et al., 1998). 
It has been well documented that PN is a potent inhibitor of NF-κB signaling 
pathway which contributes to its anti-inflammatory activity (Bork et al., 1997; Hehner et 
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al., 1998; 1999).  In contrast, relatively little is known with regards to the effects of PN 
on other signaling molecules such as AP-1 and their involvements in its anti-cancer 
activity.  The main objective of this study is to determine the mechanism(s) involved in 
the cancer chemopreventive property of PN.  The main focus is on its effect on AP-1 and 
mitogen-activated protein kinases (MAPKs) signaling cascade using JB6 murine 
epidermal cells.  The results provide evidence that the inhibitory effects on AP-1 and 
MAPK serve as one of the underlying mechanisms for the cancer chemopreventive 
property of PN. 
 
3.2 Materials and Methods 
3.2.1 Cell line and Chemicals  
 Murine epidermal cell line JB6 was obtained from Dr. Shi XL from NIOSH, USA.  
JB6 murine epidermal cells stably transfected with an AP-1 luciferase reporter plasmid 
have been reported previously (Ding et al., 1999; 2001).PN (97% pure) was purchased 
from Biomol (Plymouth Meeting, PA).  Celecoxib was kindly provided by Pfizer (New 
York, NY).  Anti p-JNK, JNK, p-p38, p38, p-Erk, Erk, p-c-Jun, c-Jun, p-ATF-2 and 
ATF-2 polyclonal antibodies were purchased from Cell Signaling (Beverly, MA).  
Secondary antibodies (horseradish peroxidase conjugated goat anti-mouse IgG and goat 
anti-rabbit IgG) and enhanced chemiluminescence substrate were from Pierce (Rockford, 
IL).  γ-p32 ATP was obtained from Perkin-Elmer (Boston, MA).  SP600125 was 
purchased from Calbiochem (San Diego, CA).  Other common chemicals were from 
Sigma-Aldrich (St. Louis, MO). 
 
 67
3.2.2 Cell culture and treatment 
All cells were cultured in MEM supplemented with 5% FBS and 100 units/ml 
penicillin and 100 μg/ml streptomycin at 37°C in 5% CO2/air atmosphere.  Cells were 
seeded in 6-well plates or 60 mm cultural dishes and starved with MEM containing 0.5% 
FBS for 24 hrs after reaching 80% confluence.  After pre-treatment with medium 
containing various chemicals at designated concentrations, cells were washed with PBS 
once and then exposed to UVB in fresh PBS.  Cells were returned to incubator with the 
addition of the previous culture medium until time of collection. 
 
3.2.3 Detection of cell viability—LDH leakage 
Activity of lactate dehydrogenase (LDH) in the medium was measured using a 
Cobas Mira S Analyser with the test kit (Abbott Laboratories, Irving, TX, USA). The 
total LDH activity was determined by ultrasonication and assessed by expressing as 
percentage LDH leakage (LDH in medium/total LDH activity x 100). 
 
3.2.4 Determination of sub-G1 cells 
 It is well established that DNA fragmentation during apoptosis may lead to 
extensive loss of DNA content and result in a distinct sub-G1 peak when analyzed using 
flow cytometry (Nicoletti et al. 1991).  Hence, sub-G1 assay was used to quantify the 
apoptotic effect of UVB and PN-UVB.  At the end of various designated treatments, cells 
were scrapped, washed, fixed and permeabilized with 70% ice-cold ethanol at 4 oC for 2 
hours.  Cells were then incubated at 37 oC for 15 min with freshly prepared PI solution 
(0.1 % Triton X-100, 200  μg / ml RNase A, and 20 μg / ml PI in PBS).  10,000 cells 
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from each group were analyzed using flow cytometry (Coulter Epics Elite ESP, Miami, 
USA), and data obtained were analyzed using WinMDI2.7 software (Scripps Institute, La 
Jolla, USA).   
 
3.2.5 DNA gel electrophoresis 
The DNA fragmentation pattern (DNA ladder), which is a hallmark of apoptosis, 
was assessed by agarose gel electrophoresis.  DNA was extracted using a DNA extraction 
kit from PureGene according to manufacturer’s protocol.  Briefly, cells were collected 
after designated treatment.  After a short centrifugation at 13,000 g for 15 seconds, Cell 
Lysis Solution was added to the cell pellet, followed by RNase A solution and 10 min 
incubation at 37 oC.  The cell lysates were then cooled for 1 min before adding Protein 
Precipitation Solution, followed by vigorous vortexing for 20 seconds.  After 
centrifugation at 13,000 g for 5 min at 4 oC, the supernatants containing the DNA were 
then precipitated with 100% isopropanol.  The samples were mixed by gentle inversion 
for 50 times and followed by centrifugation at 13,000 g for 5 min at 4 oC.  The DNA 
pellets were then washed with 70% ethanol and allowed to dry for 10-15 min.  DNA was 
then rehydrated in DNA Hydration Solution.  Five µg of DNA were then electrophoresed 
in 1.5 % agarose gel stained with EB (1 µg/ml) at 50 V in 0.5 X TBE buffer (45 mM Tris, 
45 mM boric acid, 1 mM EDTA, pH8.0), visualized under UV and photographed.   
 
3.2.6 Western blot analysis 
Cells were scrapped after the designated treatment and washed with ice-cold PBS 
twice.  Pellets were resuspended in lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 
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10% glycerol, protease inhibitor cocktail), sonicated on ice for 15 seconds, and 
centrifuged at 10,000 g for 10 minutes at 15oC.  30 μg of proteins were separated on 10% 
SDS-polyacrylamide gel in Mini-Protein II system (Bio-Rad). Following electrophoresis 
the protein was transferred to a PVDF membrane (Millipore, Bedford, MA, USA) and 
subsequently hybridized with various antibodies.  The blots were detected using the 
enhanced chemiluminescence method (Pierce) and analyzed using Kodak Image Station. 
 
3.2.7 Electrophoresis mobility shift assay (EMSA) 
Nuclear extracts were prepared according to a published method with 
modifications (Hehner et al., 1998).  JB6 cells were collected after the designated 
treatment, washed with ice-cold PBS twice and then resuspended in 120 μl of Buffer A 
(10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, protenase inhibitor 
cocktail).  After 15 minutes of incubation on ice, Nonidet P-40 was added (final 
concentration 0.3%) and tubes were vortex vigorously.  The lysates were centrifuged at 
2,000 g for 10 min at 4oC.  The resulting nuclear pellet was resuspended in 40 μl of 
Buffer B (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 450 mM NaCl, 25% glycerol, 0.2 mM 
EDTA, 0.5 mM DTT, protease inhibitor cocktail) and incubated on ice for 30 minutes.  
The nuclear extracts were collected after 15 minutes of centrifugation at 20,000 g at 4oC.  
Protein concentration was quantified using Bio-Rad protein assay kit (Hercules, CA).  All 
samples were kept at -70oC until assay.  The DNA binding reaction mixture contained 5 
μg of nuclear extract, 5 x Buffer C (100 mM HEPES, pH7.9, 20% glycerol, 1 mM DTT 
and 300 mM KCl), 2 μg poly (dI-dC), 2 μg BSA and incubate for 30 min on ice.  32P 
labeled NF-κB oligonucleotide (5’-AGTTGAGGGGACTTTCCCAGGC-3’, 3’-
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TCAACTCCCCTGAAAGGGTCCG-5’) or AP-1 oligonucleotide (5’-
CGCTTGATGAGTCGACCGGAA-3’, 3’-GCGAACTACTCAGTCGGCCTT-5’) was 
then added in a total volume of 20 μl.  The DNA-protein complexes were resolved in 5% 
polyacrylamide gel using a vertical gel electrophoresis apparatus (Gibco BRL).  Gels 
were then dried and exposed to an X-ray film (Kodak) at -70oC overnight.   
 
3.2.8 AP-1 transactivation assay 
JB6 cells stably transfected with an AP-1 luciferase reporter plasmid were 
subjected to designated treatments.  At 6 hours post UVB irradiation, the cell lysates were 
collected after the addition of cell lysis buffer (Promega).  Luciferase activity was 
measured using a luciferase assay kit (Promega).  The relative light units (RLU) were 
then determined in a luminometer (Lumi-one, Trans Orchid, Tampa, FL) for 15 seconds 
after a 5 second delay time. 
 
3.2.9 Statistical analysis 
All numeric data are presented as means ± standard deviations (SD) and analyzed 
using one-way ANOVA with Student-Newman-Keuls multiple comparisons as post-hoc 
test (SPSS 11.5).  A P value < 0.05 is considered as statistical significance.   
 
3.3 Results 
3.3.1 PN sensitizes cells to UVB-induced apoptosis in a dose-dependent manner 
In order to elucidate the mechanism(s) involved in the chemopreventive property 
of PN against UVB-induced skin cancer, a mouse epidermal cell line JB6 was used in the 
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subsequent in vitro study.  The cytotoxicity of PN was first tested on this cell line using 
LDH leakage (Figure 3.1) and DNA content analysis of sub-G1 cells (Figure 3.2).  The 
LD50 was estimated at 8.5 µM.  Next, a series of investigations were conducted to 
determine if PN has any synergistic or antagonistic effect on UVB-induced apoptosis. 
High dosage of UVB is capable of inducing apoptosis in JB6 cells and the preliminary 
experiment showed that 50 mJ/cm2 UVB was the lowest observed effect level (LOEL) 
with marginal cytotoxic effect to cells.  Pre-treating cells with non-cytotoxic 
concentrations of PN (2.5 and 5 µM) greatly enhanced UVB (50 mJ/cm2)-induced cell 
death as measured by LDH leakage (Figure 3.3) and percentage of sub-G1 cells 
determined by DNA content analysis (Figure 3.4).  Similar results were also found in 
DNA gel electrophoresis showing DNA fragmentation, a hallmark of apoptosis (Figure 
3.5).  Based on the common understanding that removal of damaged cells via apoptosis is 
an important anti-oncogenic process (Hildesheim et al., 2002; Kulms and Schwarz, 2002; 
D’Errico et al., 2003), it is thus believed that such sensitization by PN may serve as one 
of the underlying mechanisms for its chemopreventive property against UVB-induced 
skin cancer. 
 
3.3.2 PN inhibits NF-κB and AP-1 DNA binding activity as well as transcriptional 
activity of AP-1 induced by UVB 
PN is a potent inhibitor of NF-κB signaling pathway.  Indeed, pretreatment of 1-5 
µM PN significantly inhibited the UVB-induced DNA binding ability of NF-κB (Figure 
3.6).   In addition, it is well documented that AP-1 is an important transcription factor 






















Figure 3.1 PN dose-dependently induced apoptosis.  JB6 cells were treated with 
various concentrations of PN and the viability of cells was determined 
by LDH leakage 24 hours later as described in materials and methods.  
Data were presented as means ± SD from three independent 
experiments and analyzed using one-way ANOVA with Student-
Newman-Keuls multiple comparisons test.  An asterisk indicates 


























Figure 3.2 PN dose-dependently induced apoptosis.  JB6 cells were treated with 
various concentrations of PN and the viability of cells was determined 
by DNA content analysis for sub-G1 cells 24 hours later as described 
in materials and methods.  Data were presented as means ± SD from 
three independent experiments and analyzed using one-way ANOVA 
with Student-Newman-Keuls multiple comparisons test.  An asterisk 

























Figure 3.3 PN sensitizes cells to UVB-induced apoptosis.  JB6 cells were pre-
treated with 1, 2.5 or 5 µM of PN for 2 hours and subjected to UVB 
irradiation of 50 mJ/cm2.  The viability of cells was determined by 
LDH leakage 24 hours after UVB irradiation as described in materials 
and methods.  Data were presented as means ± SD from three 
independent experiments and analyzed using one-way ANOVA with 
Student-Newman-Keuls multiple comparisons test.  An asterisk 
























Figure 3.4 PN sensitizes cells to UVB-induced apoptosis.  JB6 cells were pre-treated 
with 1, 2.5 or 5 µM of PN for 2 hours and subjected to UVB irradiation of 50 
mJ/cm2.  The viability of cells was determined by DNA content analysis for 
sub-G1 cells 24 hours after UVB irradiation as described in materials and 
methods.  Data were presented as means ± SD from three independent 
experiments and analyzed using one-way ANOVA with Student-Newman-
Keuls multiple comparisons test.  An asterisk indicates statistical significance 
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Figure 3.5 PN sensitizes cells to UVB-induced apoptosis.  JB6 cells were pre-treated 
with 1, 2.5 or 5 µM of PN for 2 hours and subjected to UVB irradiation of 50 
mJ/cm2.  The viability of cells was determined by DNA fragmentation assay 
24 hours after UVB irradiation as described in materials and methods.  DNA 
fragments were resolved by electrophoresis at 50 V on 1.5% agarose gels 
impregnated with ethidium bromide, detected by UV transillumination and 












Figure 3.6 PN inhibits the UVB-induced DNA binding activity of NF-κB.  JB6 
cells were pre-treated with 1, 2.5 or 5 µM of PN for 2 hours, followed 
by UVB irradiation with 50 mJ/cm2.  Control cells were mock 
irradiated.  Cells were harvested 6 hours after UVB irradiation.  Five 
µg of nuclear extracts were subjected to EMSA as described in 





been reported to induce DNA binding activity of AP-1 in JB6 cells (Huang et al., 1997).  
As shown in Figure 3.7, 50 mJ/cm2 UVB vastly induced the AP-1 binding activity in JB6 
cells.  Pretreatment with PN (2.5-5 µM) effectively suppressed UVB-induced DNA 
binding capability of AP-1.  The effect of PN on AP-1 transcriptional activity was also 
examined in JB6 cells stably transfected with an AP-1 luciferase reporter plasmid.  Cells 
were pre-treated with 1-5 µM of PN for 2 hours and followed by UVB irradiation (50 
mJ/cm2).  Being consistent with the findings in EMSA, significant reduction of AP-1 
luciferase activity was observed with higher concentrations of PN (2.5-5 µM) (Figure 
3.8). 
 
3.3.3 PN inhibits UVB-induced phosphorylations of c-Jun and ATF-2 
Both c-Jun and ATF-2 are important components of AP-1 complex (Karin et al., 
1997).  It has been reported previously that UV-induced AP-1 DNA binding is 
independent of new protein synthesis, and both Jun and ATF-2 activation occur as a 
result of post-translational modification involving changes in the phosphorylation states 
(Buscher et al., 1988; Devary et al., 1991; van Dam et al., 1995).  Thus, further 
investigations were conducted to test if PN suppresses UVB-induced AP-1 activation via 
inhibition of the phosphorylation states of its key components.  As shown in Figure 3.9A, 
pre-treatment with 5 µM of PN completely blocked UVB-induced c-Jun phosphorylation 
at both Ser63 and Ser73 sites.  No changes in total protein level for c-Jun were detected 
in cells treated with either UVB and/or PN.  Similar inhibition on UVB-induced ATF-2 











Figure 3.7 PN inhibits the UVB-induced DNA binding activity of AP-1.  JB6 cells were 
pre-treated with 1, 2.5 or 5 µM of PN for 2 hours, followed by UVB 
irradiation with 50 mJ/cm2.  Control cells were mock irradiated.  Cells were 
harvested 6 hours after UVB irradiation.  Five µg of nuclear extracts were 

















Figure 3.8 PN inhibits the UVB-induced transcriptional activity of AP-1.  JB6 
cells stably transfected with an AP-1 luciferase reporter plasmid were 
pre-treated with 1, 2.5 or 5 µM of PN for 2 hours, followed by UVB 
irradiation with 50 mJ/cm2.  Control cells were mock irradiated.  Cells 
were harvested 6 hours after UVB irradiation.  Luciferase activity was 
determined as described in Materials and Methods.  Data were 
presented as means ± SD from three independent experiments and 
analyzed using one-way ANOVA with Student-Newman-Keuls 
multiple comparisons test.  An asterisk indicates statistical significance 
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Figure 3.9 PN inhibits the UVB-induced phosphorylations of (A) c-Jun and (B) ATF-2.  
JB6 cells were pre-treated with 1, 2.5 or 5 µM of PN, 20 µM of SP600125, or 
10 µM of SB203580 for 2 hours and then subjected to UVB irradiation of 50 
mJ/cm2.  Cells were harvested 2 hours after UVB irradiation.  Thirty µg of 
proteins were separated on 10% SDS-polyacrylamide gels and the subsequent 
membranes were hybridized with anti-p-c-Jun, c-Jun, p-ATF-2, ATF-2 
antibodies.  α-Tubulin was blotted as loading control.  The blots were detected 
using the enhanced chemiluminescence method (Pierce) and analyzed using 
Kodak Image Station 440. 
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believed that PN suppresses UVB-elicited AP-1 activation via reduced phosphorylation 
levels of its key components such as c-Jun and ATF-2.   
 
3.3.4 PN blocks UVB-induced MAPK pathways 
JNK and p38 are two main groups of MAPKs that are directly involved in UVB-
elicited AP-1 activation (Adler et al., 1996; Chen and Bowden, 2002).  c-Jun and ATF-2 
serve as direct downstream targets for JNK and p38, respectively.  In order to further 
understand the mechanisms involved in the inhibitory effect of PN on UVB-induced AP-
1 activation, a series of experiments were conducted to study if PN acts on UVB-elicited 
JNK and p38 activation.  Pre-treatment with 5 μM of PN completely blocked UVB-
induced JNK phosphorylation without affecting the total JNK protein level (Figure 
3.10A).  Similar inhibitory effect on UVB-induced p38 phosphorylation was also 
observed in cells pre-treated with PN (Figure 3.10B).  Therefore, it is believed that PN 
suppresses UVB-mediated AP-1 activation through its inhibitory effects on JNK and p38. 
 
3.3.5 PN sensitizes UVB-induced apoptosis via JNK and p38 
It is still controversial with regards to the exact role of JNK and p38 in UV-
induced apoptosis.  In mouse embryonic fibroblasts, JNK has been shown to be required 
for UV-induced cell death (Tournier et al., 2000).  On the contrary, there is evidence 
indicating that JNK and p38 act as cell survival/anti-apoptotic mechanism in UV-treated 
cells (Wisdom et al., 1999; Ivanov and Ronai, 2000; Chouinard et al., 2002).  As shown 
above (Figure 3.4), PN effectively sensitizes UVB-induced apoptosis in JB6 cells.  
Notably, similar sensitization was also found in cells pre-treated with SP600125 (a 
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specific inhibitor of JNK) or SB203580 (a specific inhibitor of p38), although to a less 
extent (Figure 3.11).  The effectiveness and specificity of these two inhibitors were 
confirmed by the significant reduction in phosphorylation of their respective targets 
(Figure 3.9 and 10).  Data from this experiment thus provide indirect evidence that PN 
may sensitize UVB-induced apoptosis via its inhibitory effect on JNK and p38.  It 
appears that both JNK and p38 contribute to the cell survival mechanisms in UVB-treated 
JB6 cells, based on the observation that PN as a dual-inhibitor of JNK and p38 are much 
more effective than the individual inhibitor for sensitizing UVB-induced apoptotic cell 
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Figure 3.10 PN inhibits the UVB-induced phosphorylations of (A) JNK and (B) 
p38.  JB6 cells were pre-treated with 1, 2.5 or 5 µM of PN, 20 µM of 
SP600125, or 10 µM of SB203580 for 2 hours and then subjected to 
UVB irradiation of 50 mJ/cm2.  Cells were harvested 2 hours after 
UVB irradiation.  Thirty µg of proteins were separated on 10% SDS-
polyacrylamide gels and the subsequent membranes were hybridized 
with anti-p-JNK, JNK, p-p38, p38 antibodies.  α-tubulin was blotted as 
loading control.  The blots were detected using the enhanced 






















           
Figure 3.11 PN, SP600125, and SB203580 sensitize cells to UVB-induced 
apoptosis.  JB6 cells were pretreated with 5 µM of PN, 20 µM of 
SP600125, or 10 µM of SB203580 for 2 hours and then subjected to 
UVB irradiation of 50 mJ/cm2.  The viability of cells was determined 
using PI staining in sub-G1 assay at 24 hours post-UVB treatment.  
Data were presented as means ± SD from three independent 
experiments and analyzed using one-way ANOVA with Student-
Newman-Keuls multiple comparisons test.  An asterisk indicates 
statistical significance with a P-value < 0.05. 
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 3.4 Discussion 
Nuclear transcriptional factors such as AP-1, NF-κB, NF-AT and STATs have been 
reported to be involved in the UVB-induced signaling pathway (Angel et al., 2001; 
Siebenlist et al., 1995; Huang et al., 2000; Zhang et al., 2001).  In order to further 
understand the possible mechanism(s) contributing to the observed chemopreventive 
property of PN, we investigated the effects of PN on AP-1 and the related MAPKs 
signaling cascade using JB6 murine epidermal cells.  AP-1 plays a key role in pre-
neoplastic to neoplastic transformation in cell culture and the blockage of AP-1 activities 
has been shown to inhibit cell transformation (Dong et al., 1994).  Moreover, AP-1 has 
been shown to regulate apoptosis, with both pro-apoptotic and anti-apoptotic function 
(Shaulian and Karin, 2002).  It appears that the exact outcome of AP-1 manipulations is 
highly tissue- and developmental stage-specific.  Results from the present study 
demonstrated that PN pre-treatment inhibits the UVB-induced DNA binding (Figure 3.7) 
and transcriptional activity of AP-1 (Figure 3.8) in addition to its well known suppressive 
effect on NF-κB (Figure 3.6).  Two of the major components of AP-1 complex, c-Jun and 
ATF-2, can activate AP-1 via post-translational modification involving changes in the 
phosphorylation states (Buscher et al., 1988; Devary et al., 1991; van Dam et al., 1995).  
In response to UV, c-Jun is rapidly phosphorylated at both Ser63 and Ser73 sites along 
with ATF-2.  The data showed that PN subdues UVB-induced AP-1 transactivation via 
blockage of c-Jun and ATF-2 phosphorylations (Figure 3.9A and B).  The outcome of 
these series of inhibitions seem to lead to massive sensitization to UVB-induced 
apoptosis (Figure 3.4), suggesting an anti-apoptotic role of AP-1.  Such anti-apoptotic 
function of AP-1 and c-Jun has been reported previously.  Wisdom and co-workers (1999) 
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noted that c-Jun protects cells from UV-induced apoptosis and phosphorylation of c-Jun 
on Ser63 and Ser73 is required for such protection.  Moreover, Ivanov and colleagues 
(2001) demonstrated that c-Jun protects cells against UV-induced cell death via co-
operation with STAT3 to suppress transcription of Fas.   
The UV-activated signal transduction pathway is primarily mediated by mitogen-
activated protein kinases (MAPKs).  Mammals express at least four distinctly regulated 
groups of MAPK: Erks, JNK, p38, and Erk5 (Chang and Karin, 2001).  All MAPKs are 
activated by dual phosphorylation on threonine and tyrosine at T-X-Y motifs within the 
activation loop.  Once activated, they translocate to the nucleus and phosphorylate target 
transcription factors.  In response to UV, key MAPKs such as JNK and p38 are activated, 
which in turn phosphorylate c-Jun at Ser-63 and Ser-73 sites and ATF-2, respectively 
(Devary et al., 1991; van Dam et al., 1995).  It is rather controversial in regards to the 
exact role of JNK in UV-mediated apoptosis.  For instance, JNK has been shown to be 
required for UV-induced apoptotic cell death in mouse embryonic fibroblasts (Tournier et 
al., 2000), while other studies demonstrated the anti-apoptotic role of JNK in UV-
induced apoptosis (Wisdom et al., 1999; Ivanov et al., 2001).  Results from the present 
study showed that the inhibition of JNK leads to sensitization of JB6 cells to UVB-
induced apoptosis, suggesting an anti-apoptotic role of JNK in our system (Figure 3.11).  
In general, the exact role of JNK in apoptosis varies depending on a number of factors 
that include the nature of the stimuli, cell type, the duration of activation and more 
importantly, the interaction of other signaling pathway such as NF-κB and the PI3K-
AKT cascades (Davis, 2000; Lamb et al., 2003; Lin, 2003).  The involvement of those 
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cell survival signaling pathways in PN-mediated cell death sensitization remains to be 
further investigated. 
In the present study, the potent inhibitory effect of PN on UVB-induced p38 
activation (Figure 3.10) was also noted, and p38 inhibition leads to sensitization of cells 
to UVB-induced apoptosis (Figure 3.11), implying an anti-apoptotic role of p38 in UVB-
induced apoptotic cell death.  Although it is still controversial regarding the exact role of 
p38 in apoptosis, p38 has been reported to protect cells from UV-induced apoptosis 
through down regulation of NF-κB activity and Fas expression (Ivanov and Ronai, 2000).  
Some other mechanisms have also been proposed to be involved in the anti-apoptotic 
function of p38.  For instance, the p38 MAPK inhibitor SB203580 can trigger a 
significant, Ras-independent activation of c-Raf in certain cell lines in the concentration 
range of 8-25 µM (Hall-Jackson et al., 1999; Kalmes et al., 1999).  Activated Raf may 
phosphorylate and inactivate Bad, a pro-apoptotic member of the Bcl-2 family of proteins, 
or up-regulate the transcription of pro-survival genes to prevent cytochrome c release and 
subsequently apoptosis (Bonni et al., 1999).  Furthermore, Raf-1 has been shown to 
promote cell survival by antagonizing apoptosis signal-regulating kinase 1 (ASK1), an 
important mediator of apoptotic signaling (Chen et al., 2001).  In the present study, PN 
has been shown to be a dual inhibitor of both JNK and p38 in UVB-treated cells (Figure 
3.10).  Incidentally, the PN-elicited sensitization of JB6 cells to UVB-induced apoptosis 
is twice as strong as with the individual JNK and p38 inhibitor (Figure 3.11).  These 
findings suggest that both JNK and p38 contribute to the cell survival mechanisms in 
UVB-treated cells. 
 89
UV exposure could result in direct or indirect DNA damage, and the damage is 
normally repaired by a nucleotide excision repair (NER) mechanism (Thoma, 1999).  
Most of the irreparable DNA-damaged cells will be eliminated through apoptosis, as 
evident in skin with the appearance of sunburn cells (Kulms and Schwarz, 2002).  
However, not all cells with irreparable DNA damage will undergo apoptosis.  DNA 
lesions that are not repaired or incorrectly repaired may lead to mutations and 
subsequently carcinogenesis.  Therefore, the removal of damaged cells through 
sensitizing cells to apoptosis denotes an effective mean in preventing carcinogenesis 
process (Hildesheim et al., 2002; Kulms and Schwarz, 2002; D’Errico et al., 2003).   
 In summary, the data from this study for the first time demonstrated the 
synergistic effect of PN and UVB in sensitizing cells to apoptosis.  Such sensitization 
appears to be mediated through inhibition on AP-1, JNK and p38 signaling pathways and 
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 4.1 Introduction: 
Feverfew (Tanacetum parthenium) has been used as a herbal plant for centuries in 
Europe, with known anti-microbial and anti-inflammatory properties (Brown et al., 1997; 
Jain and Kulkarni, 1999).  PN, a sesquiterpene lactone, is one of principal bioactive 
components of this plant.  It is believed that the bioactivity of PN is mediated via the 
highly electrophilic α-methylene-γ-lactone ring and an epoxide residue that are capable of 
interacting rapidly with nucleophillic sites of biological molecules (Macias et al., 1997; 
Zhang et al., 2005).  PN is a potent inhibitor of DNA synthesis and cell proliferation in a 
number of cancer cell lines (Woynarowski and Konopa, 1981; Hall et al., 1988; Ross et 
al., 1999).  In addition, PN has been reported to induce apoptosis via caspase activation 
and mitochondria dysfunction (Wen et al., 2002), disruption in intracellular thiols and 
calcium equilibrium (Zhang et al., 2004a), as well as activation of pro-apoptotic Bcl-2 
family proteins (Zhang et al., 2004c).  On the other hand, PN also has been shown to 
sensitize cells to apoptosis induced by various stimuli such as TNF-α  and TRAIL, 
presumably through its action on activator protein-1 (AP-1) signaling pathway (Zhang et 
al., 2004b; Nakshatri et al., 2004).  The results from chapter 3 have also shown the 
sensitization activity of PN on UVB-induced apoptosis in JB6 cells.  The in vivo anti-
cancer activity of PN has been studied recently.  For instance, the results from chapter 2 
demonstrated that PN possesses strong chemopreventive property against UVB-induced 
skin cancer in SKH-1 hairless mice, whereas Sweeney and co-workers (2005) revealed 
that PN in combination with docetaxel is capable of reducing metastasis and improving 
survival in xenograft model of breast cancer.  
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The electromagnetic spectrum of ultraviolet (UV) can be grouped into UVA (320-400 
nm), UVB (280-320 nm) and UVC (200-280 nm).  UVB exposure is the main etiological 
factor for non-melanoma skin cancer in human (Fry and Ley, 1989).  The mechanism(s) 
of UVB-induced skin cancer have not been fully understood. Several transcriptional 
factors including AP-1, nuclear transcription factor-kappa B (NF-κB), nuclear factor of 
activated T cells (NF-AT), and signal transducers and activators of transcription have 
been linked to the tumor-promoting ability of UVB (Angel et al., 2001; Siebenlist et al., 
1995; Huang et al., 2000; Zhang et al., 2001). 
 Protein kinase C (PKC) is a group of serine/threonine kinases that regulate many 
cellular functions such as proliferation, differentiation, transformation, survival and 
apoptosis (Yang and Kazanietz, 2003).  PKC can be classified into 3 groups based on the 
co-factors required for activation: 1) the Ca2+ and diacylglycerol (DAG)-dependent 
classical or conventional PKC that consists of isotypes α, β1, β2 and γ; 2) the DAG-
dependent, Ca2+-independent novel PKC that consist of δ, η, ε and θ, and 3) the DAG- 
and Ca2+-independent atypical PKC that consist of ι/λ and ζ.  The consequences of PKC 
activation by UVB is rather cell type specific and could lead to inhibition on cell 
proliferation or even induction of apoptosis.  Among all, PKCδ seems to be the main 
PKC subtype with pro-apoptotic functions in response to various extracellular stimuli 
including UVB (Chen et al., 1999; Brodie and Blumberg, 2003) whereas PKCζ has been 
shown to be anti-apoptotic in response to UV (Berra et al., 1997; Frutos et al., 1999).   
 As shown in chapter 3, suppression of mitogen activated protein kinase and AP-1 
signaling cascade by PN contributes to its sensitization effect on UVB-induced apoptosis 
in JB6 cells.  It is also known that certain subtypes of PKC regulate the MAPK-AP-1 
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pathway in UVB-treated cells (Chen et al., 1999; Huang et al., 2000).  Hence, the main 
objective of this study is to explore the involvement of PKC so as to further understand 
the underline mechanism(s) of the chemopreventive property of PN.  The data 
demonstrate for the first time that PN selectively inhibits the UVB-induced PKCζ 
activation while further enhances that of PKCδ, both contribute to the sensitization effect 
of PN on UVB-induced apoptosis in murine epidermal JB6 cells. 
 
4.2 Materials and Methods 
4.2.1 Cell line and chemicals 
Murine epidermal cell line JB6 was obtained from Dr. Shi XL from NIOSH, USA.  
PN (97% pure) was purchased from Biomol (Plymouth Meeting, PA).  Anti p-JNK, JNK, 
p-p38, and p38 polyclonal antibodies were purchased from Cell Signaling (Beverly, MA), 
while anti HA, PKC-δ and ζ polyclonal antibodies were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, CA).  Secondary antibodies (horseradish peroxidase 
conjugated goat anti-mouse IgG and goat anti-rabbit IgG) and enhanced 
chemiluminescence substrate were from Pierce (Rockford, IL).  γ-p32 ATP was obtained 
from Perkin-Elmer (Boston, MA).  SP600125 was purchased from Calbiochem (San 
Diego, CA).  PKC inhibitors GF109203X and rotterlin were purchased from Calbiochem 
(San Diego, CA).  Other common chemicals were from Sigma-Aldrich (St. Louis, MO).  





4.2.2 Cell culture and treatment 
JB6 murine epidermal cells were cultured in MEM supplemented with 5% FBS 
and 100 units/ml penicillin and 100 μg/ml streptomycin at 37°C in 5% CO2/air 
atmosphere as described earlier.  Cells were seeded in 60 mm cultural dishes and starved 
with MEM containing 0.5% FBS for 24 hrs after reaching 80% confluence.  After pre-
treated with various reagents at designated conditions, cells were washed with PBS once 
and then exposed to UVB in fresh PBS.  UVB was delivered through a bank of FS24 
lamps (Light Sources Inc., Orange, CT) with spectral irradiance of 280-400 nm, 80% of 
which in the UVB region (280-320 nm) and with a peak around 313 nm.  The emitted 
UVB dose was quantified using a phototherapy radiometer (International Light, 
Newburyport, MA) equipped with IL SED 240 detector.  Cells were returned to incubator 
with the addition of the previous culture medium until time of collection.   
 
4.2.3 Transient transfection 
Wild-type and dominant negative (DN) PKCδ and ζ plasmids were kindly 
provided by Dr. JW Soh from Inha University, Incheon, Korea.  As described previously 
(Soh and Weinstein, 2003), pHACE-PKC-WT expression plasmids were generated by 
ligating full-length open reading frames of different PKC isoforms into pHACE digested 
with EcoRI.  On the other hand, pHACE-PKC-DN expression plasmids were generated 
by ligating full-length open reading frames of PKC isoforms with a dominant negative 
(DN) (K to R or K to M) point mutation at the ATP binding site into pHACE digested 
with EcoRI.  DN-p38α and DN-p38β2 plasmids were gifts from Dr. J Han (Scripps 
Research Institute, La Jolla, CA, USA).  As described before, p38  double mutant (p38
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(AF)) was created by substituting Thr188 with Ala and Tyr190 with Phe using a PCR-based 
procedure(Jiang et al., 1996) , whereas the plasmid DN-Flag-p38α MAP kinase was 
prepared using the expression vector pCMV5 and the p38 cDNA (Zhang et al., 1995). 
The flag epitope tag DYKDDDDK was added to the amino-terminal region by PCR 
recombination.  In the present study, cells were co-transfected with designated PKC 
plasmids or and a transfection marker pDsRed (Clontech, Palo Alto, CA) using 
LipofectAMINE reagent (Invitrogen, Carlsbad, CA) according to manufacturer’s protocol.  
Cells were subjected to various treatment 24 hours after transfection. 
 
4.2.4 Determination of apoptotic cell death 
In this series of experiments, cells were first transiently transfected with various 
PKC plasmids and pDsRed fluorescence protein.  Apoptotic cell death was then 
determined using DNA content analysis coupled with flow cytometry after 4’,6-
diamidino-2-phenylindole (DAPI) staining.  Briefly, cells were scrapped, washed, 
incubated with 0.5% para-formaldehyde for 1 hour at room temperature at the end of 
various designated treatments.  Cells were then fixed and permeabilized with 70% ice-
cold ethanol at 4 oC for 2 hours.  Cells were then incubated for 15 min at room 
temperature with freshly prepared DAPI solution (100 mM Tris, pH7.4, 150 mM NaCl, 1 
mM CaCl, 0.5 mM MgCl, 0.1 % Nonidet P-40).  20,000 cells from each group were 
analyzed by flow cytometry using Becton Dickinson FACSVantage SE system (Franklin 
Lakes, NJ) (Benhar et al., 2001).  Only those transfected cells with expression of the red 
fluorescence protein were then gated for analyzing the percentage of sub-G1 cells using 
WinMDI 2.7 software (Scripps Institute, La Jolla, USA). 
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4.2.5 PKC translocation assay 
PKC translocation assay was performed based on a published method (Chen et al., 
1999) with modifications.  In brief, , 15 minutes after UVB irradiation cells were washed 
once with ice-cold PBS and then sonicated in homogenization buffer A (20 mM Tris-HCl, 
pH8.0, 10 mM EGTA, 2mM EDTA, 2 mM DTT, 1 mM PMSF and protease inhibitor 
cocktail) for 10 seconds on ice.  The lysate was then centrifuged at 100,000 g for 1 hour 
at 4 oC.  The supernatant was collected as the cytosolic fraction.  The pellet was then 
resuspended in homogenization buffer B (with 1% Triton X-100 in buffer A) and 
sonicated for another10 seconds on ice.  The suspension was centrifuged at 15,000 g for 
15 min at 4 oC.  The supernatant was collected as the membrane fraction.  Thirty μg of 
proteins were separated on 8% SDS-polyacrylamide gel in Mini-Protein II system (Bio-
Rad).  Following electrophoresis the protein was transferred to a PVDF membrane 
(Millipore, Bedford, MA, USA) and subsequently hybridized with anti-PKCδ and ζ 
antibodies.  The blots were detected using the enhanced chemiluminescence method 
(Pierce) and analyzed using Kodak Image Station. 
 
4.2.6 PKC kinase assay 
PKC kinase assay was performed according to a published method (Soh and 
Weinstein, 2003) with modifications.  Briefly, cells were harvested 30 min after UVB 
irradiation in PKC lysis buffer (50 mM HEPES, pH7.5, 150 mM NaCl, 0.1% Tween-20, 
1 mM EDTA, 2.5 mM EGTA, 10% glycerol, 0.1 mM PMSF, 1 mM NaF, 0.1 mM 
Na3VO4, 10 mM β-glycerophosphate, protease inhibitor cocktail).  The cell lysate was 
then centrifuged at 12,000 g for 15 min at 4 oC and the supernatant was collected as 
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cellular protein.  400 µg of protein was immunoprecipitated with anti-PKC antibodies (4 
µg) overnight and followed by incubation with protein G-sepharose for 1 hour.  The 
immunoprecipitates were washed 5 times with ice-cold kinase buffer (50 mM HEPES, 
pH7.5, 10 mM MgCl2, 1 mM DTT, 2.5 mM EGTA, 1 mM NaF, 0.1 mM Na3VO4, 10 mM 
β-glycerophosphate).  The kinase assay was initiated by adding 30 µl of kinase buffer 
containing 10 µg of GST-MARCKS substrate, 0.5 µCi of [γ-32P] ATP and protease 
inhibitor cocktail.  The reaction was performed for 30 min at 30 oC and was terminated 
by adding 3x sampler buffer.  All reaction mixes were then boiled for 5 min before being 
separated on a 10% SDS-polyacrylamide gel in a Mini-Protein II system (Bio-Rad).  Gels 
were then dried and exposed to an X-ray film (Kodak) at room temperature. 
 
4.2.7 PKC activity assay 
 The activity of PKC kinase was studied using another published method with 
modification (Sando, 2003).  Briefly, cells were harvested 30 min after UVB irradiation 
in PKC lysis buffer (50 mM HEPES, pH7.5, 150 mM NaCl, 0.1% Tween-20, 1 mM 
EDTA, 2.5 mM EGTA, 10% glycerol, 0.1 mM PMSF, 1 mM NaF, 0.1 mM Na3VO4, 10 
mM β-glycerophosphate, protease inhibitor cocktail).  The cell lysate was then 
centrifuged at 12,000 g for 15 min at 4 oC and the supernatant was collected as cellular 
protein.  400 µg of protein was immunoprecipitated with anti-PKC antibodies (4 µg) 
overnight and followed by incubation with protein G-sepharose for 1 hour.  The IP 
complexes were then washed twice with Buffer A (1 x PBS, 1% NP-40, and 1 mM 
PMSF), twice with Buffer B (10 mM Tris, pH7.5, and 0.5 M LiCl), twice with Buffer C 
(10 mM Tris, pH7.5, 1 mM EDTA, and 50 mM NaCl), and once with kinase buffer (10 
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mM MOPS, 5 mM MgCl2, and 0.3 mM CaCl2).  The kinase activity was initiated by 
adding 30 µl of kinase buffer containing 10 µg of MARCKS substrate, 0.5 µCi of [γ-32P] 
ATP and protease inhibitor cocktail.  The reaction was performed for 6 min at 30 oC and 
was terminated by adding 3 µl of stop solution (2 M ATP and 0.5 M EDTA, pH8.0).  The 
reaction mixture was then transferred to a P81 ion-exchange paper square (2 x 2 cm, 
Whatman International, Maidstone, UK).  These P81 ion-exchange papers were then 
washed thrice with 75 mM orthophosphoric acid and once with 95% ethanol.  The papers 
were allowed to dry before subjected to scintillation counting in 2 ml of scintillation fluid 
using Berkman LS 6000 Liquid scintillation counting system (Berkman Coulter Inc., 
Fullerton, CA, USA).  
 
4.2.8 Western blot analysis 
Cells were scrapped after the designated treatment and washed with ice-cold PBS 
twice.  Pellets were resuspended in lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 
10% glycerol, protease inhibitor cocktail), sonicated on ice for 15 seconds, and 
centrifuged at 10,000 g for 10 minutes at 15oC.  30 μg of proteins were separated on 10% 
SDS-polyacrylamide gel in Mini-Protein II system (Bio-Rad). Following electrophoresis 
the protein was transferred to a PVDF membrane (Millipore, Bedford, MA, USA) and 
subsequently hybridized with various antibodies.  The blots were detected using the 





4.2.9 Statistical analysis 
All numeric data are presented as means ± standard deviations (SD) from at least 
3 independent experiments and analyzed using one-way ANOVA with student-Newman-
Keul as post-hoc comparison.  A P value < 0.05 is considered as statistically significance. 
 
4.3 Results 
4.3.1 PN sensitizes UVB-induced apoptosis via PKC-dependent pathways 
The findings from chapter 3 demonstrated that PN is capable of sensitizing JB6 
cells to UVB-induced apoptosis via MAPK-AP-1 signaling pathway.  It is known that 
UVB activates PKC and PKC regulates the MAPK-AP-1 signaling pathway (Bode and 
Dong, 2003).  The involvement of PKC in PN-sensitized UVB-induced apoptosis was 
first tested using 2 PKC inhibitors.  As shown in Fig. 4.1, pre-treatment with GF109203X, 
a pan-PKC inhibitor also sensitizes cells to UVB-induced apoptosis, although to a lesser 
extent than PN.  In contrast, pre-treatment with a specific PKCδ inhibitor rotterlin is 
capable of completely protecting cells from apoptosis induced by UVB alone or PN plus 
UVB (Fig. 4.2).  Data from this study thus suggested that PKCδ is critical in both UVB 
and PN-UVB induced apoptosis, consistent with some of the earlier reports that PKCδ 
possesses mainly pro-apoptotic function in response to various extracellular stimuli 
(Chen et al., 1999; Brodie and Blumberg, 2003). 
 
4.3.2 PN selectively regulates different isoforms of PKC in UVB-induced activations 
UVB is known to activate certain subtypes of PKC such as PKCδ and PKCζ (Chen et 











































Figure 4.1 Involvement of PKC in cell death induced by PN+UVB.  JB6 cells 
were pre-treated with 5 µM PN for 2 hours or 20 µM GF109203X (a 
pan-specific PKC inhibitor) for 1 hour and then subjected to 50 
mJ/cm2 of UVB.  In some groups, cells were first pre-treated with 
GF109203X for 1 hour, followed by PN and UVB.  Apoptosis was 
quantified with DNA content/sub-G1 analysis 24 hours after UVB 
irradiation.  Data were presented in means ± SD from 3 independent 
experiments.  An asterisk indicates statistical significance comparing 
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Figure 4.2 Involvement of PKCδ in cell death induced by PN+UVB.  JB6 cells 
were pre-treated with 5 µM PN for 2 hours or 1 µM rotterlin (a 
specific PKCδ inhibitor) for 1 hour and then subjected to 50 mJ/cm2 of 
UVB.  In some groups, cells were first pre-treated with rotterlin for 1 
hour, followed by PN and UVB.  Apoptosis was quantified with DNA 
content/sub-G1 analysis 24 hours after UVB irradiation.  Data were 
presented in means ± SD from 3 independent experiments.  An asterisk 
indicates statistical significance comparing to the untreated control 




translocation from the cytosol to membrane (Sando, 2003).  In this study, the UVB-
induced PKC activation was first measured by determining PKC membrane translocation.  
Figure 4.3 provides convincing evidence that UVB induced membrane translocations of 
PKCδ and ζ 15 min post-irradiation in JB6 cells.  Similar changes were also observed in 
other PKC isoforms such as PKCη and PKCλ (data not shown).  When cells were pre-
treated with 5 µM of PN, the UVB-induced translocation of PKCζ was significantly 
inhibited (Fig. 4.3b) while the translocation of PKCδ was further enhanced (Fig. 4.3a).  A 
consistent pattern of changes was also detected when the activation of PKC was 
measured using the in vitro PKC kinase assay as well as PKC kinase activity assay: PN 
inhibited the UVB-induced activation of PKCζ (Fig. 4.4b and Figure 4.5) while further 
enhanced that of PKCδ (Fig. 4.4a and Figure 4.6).   
In order to further understand the differential roles of PKC isoforms on the sensitization 
effect of PN on UVB-induced apoptosis, cells were transiently transfected with wild-type 
or DN forms of PKCδ or ζ plasmids, together with pDsRed as the transfection marker, 
followed by PN-UVB treatment.  When the morphological changes of apoptotic cell 
death were examined under an inverted fluorescence microscope, it was found that the 
DN-PKCδ transfected cells became rather resistant to PN-UVB-induced apoptosis while 
the wild-type PKCδ transfected cells underwent massive apoptosis upon PN-UVB 
treatment (Fig. 4.7).  On the contrary, over-expression of wild-type PKCζ offered 
significant protection against PN and UVB-induced apoptosis (Fig. 4.7).  Such findings 
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Figure 4.3 PKC activation in cells treated with PN and UVB measured by PKC 
membrane translocation. (a) PN enhanced UVB-induced PKCδ 
membrane translocation; (b) PN inhibited UVB-induced PKCζ 
membrane translocation.  Cells were pre-treated with 5 µM PN for 2 
hours, 20 µM GF109203X or 1 µM rotterlin for 1 hour and then 
subjected to 50 mJ/cm2 of UVB. Cells were harvested 15 min after 
UVB irradiation.  Thirty µg of cytosolic or membrane proteins were 
separated on 8% SDS-polyacrylamide gels and blotted with respective 
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Figure 4.4 PKC activation in cells treated with PN and UVB measured by PKC 
kinase assay. (a) PN enhanced UVB-induced PKCδ kinase activity; 
(b) PN inhibited UVB-induced PKCζ kinase activity.  Cells were pre-
treated with 5 µM PN for 2 hours, 20 µM GF109203X or 1 µM 
rotterlin for 1 hour and then subjected to 50 mJ/cm2 of UVB. Cells 
were harvested 30 min after UVB irradiation. Cell lysate was 
immunoprecipitated with anti-PKCs antibodies and then subjected to 
PKC kinase assay as described in Materials and Methods.  Data were 

































Figure 4.5 PN sustained UVB-induced PKCδ kinase activity measured by PKC 
activity assay.  Cells were pre-treated with 5 µM of PN for 2 hours or 
1 µM of rotterlin for 1 hour before subjected to 50 mJ/cm2 of UVB.  
Cells were harvested 30 min after UVB irradiation.  Cell lysate was 
immunoprecipitated with anti-PKCs antibodies and then subjected to 
PKC activity assay as described in Materials and Methods.  An asterisk 
indicates statistical significance comparing to the UVB-treated only 

































Figure 4.6 PN inhibited UVB-induced PKCζ kinase activity measured by PKC 
activity assay.  Cells were pre-treated with 5 µM of PN for 2 hours or 
20 µM of GF109203X for 1 hour before subjected to 50 mJ/cm2 of 
UVB.  Cells were harvested 30 min after UVB irradiation.  Cell lysate 
was immunoprecipitated with anti-PKCs antibodies and then subjected 
to PKC activity assay as described in Materials and Methods.  An 
asterisk indicates statistical significance comparing to the UVB-treated 





























Figure 4.7 Impact of PKC over-expressions on apoptosis induced by PN+UVB. 
JB6 cells were transiently transfected with pcDNA, wild-type or DN 
forms of PKCδ or ζ and a transfection marker pDsRed as described in 
Materials and Methods.  Twenty-four hours after transfection, cells 
were pre-treated with 5 µM of PN for 2 hours and then subjected to 50 
mJ/cm2 of UVB.  The morphological changes of apoptotic cell death 
were examined under an inverted fluorescence microscope 24 hours 




In order to obtain more quantitative data, another approach was used by analyzing 
DNA content/sub-G1 cells among those transfected cells (Fig. 4.8).  Being consistent 
with the morphological changes, cells transfected with DN-PKCδ or wild-type PKCζ 
were resistant to PN and UVB-induced apoptotic cell death (Fig. 4.9 and 4.10).  In 
contrast, over-expression of wild-type PKCδ or DN-PKCζ significantly enhanced cell 
death induced by PN and UVB treatment (Fig. 4.9 and 4.10). 
 
4.3.3 PKCζ acts upstream of p38 MAPK but not JNK 
Previous findings from chapter 3 illustrated that the MAPK-AP-1 pathway is one of the 
molecular targets of PN.  Certain PKC isoforms have been shown to regulate the MAPK 
signaling cascade.  For example, PKCδ has been reported to affect the UVB- induced 
phosphorylations of Erk 1/2 and JNK (Chen et al., 1999) while PKCζ primarily targets 
Erk 1/2 (Huang et al., 2000).  Since PKCs are known to response differently depending 
on cell type and stimuli, the effect of PKCδ and ζ on MAPK activation was first verified 
in our experimental system.  The results confirmed that PN pre-treatment is capable of 
blocking UVB-induced p38 activation, similar to the effect of a specific p38 inhibitor 
SB203580 (Fig. 4.11a).  Interestingly, pre-treatment with a pan-specific PKC inhibitor, 
GF109203X, inhibited the UVB-induced p38 activation to certain extent, while the PKCδ 
specific inhibitor, rotterlin, has no effect on p38 activation (Fig. 4.11a).  Next the 
relationship between PKC and p38 activation was examined using genetic approaches.  
When cells were transfected with wild-type or DN-PKCδ, neither UVB-induced p38 
activation nor the inhibitory effect of PN was affected as compared to the pcDNA-
transfected control (Fig. 4.11b).  Intriguingly, over-expression of wild-type PKCζ 
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abolished the inhibitory effect of PN on UVB-induced p38 phosphorylation, while the 
over-expression of DN-PKCδ even completely blocked UVB-induced p38 activation (Fig. 
4.11c).  Therefore, these data clearly suggest that it is PKCζ, but not PKCδ, that is 
responsible for UVB-induced p38 activation.   
Since PN is able to inhibit the phosphorylation of JNK induced by UVB as shown 
previously (Chapter 3), the functional role of PKC in UVB-induced JNK activation was also 
examined.  As shown in Fig. 4.12a, the two PKC inhibitors had no effect on UVB-induced 
JNK activation.  Furthermore, over-expressions of the two DN forms of PKCδ or PKCζ had 
no effect on either UVB-induced JNK activation or the inhibitory effect of PN (Fig. 4.12b).  
In contrary to the previously findings (Chen et al., 1999; Huang et al., 2000), the total levels 
of MAPKs are not affected by the over-expressions of either wild-type or DN forms of PKCδ 
and ζ.  It is thus believed that UVB-induced JNK activation is independent of PKC activation. 
In order to further confirm the functional linkage between PKCζ and p38 activation 
in protection of apoptosis induced by PN and UVB, JB6 cells were transiently transfected 
with wild-type PKCζ together with DN-p38α and DN-p38β2 plasmids.  As shown in Fig. 
4.13a, over-expression of DN-p38α and DN-p38β2 completely inhibited UVB-induced 
p38 activation.  More importantly, while the over-expression of wild-type PKCζ offered 
significant protection against apoptosis induced by PN+UVB, the co-transfection of the 
DN forms of p38 protein abolished the protective effect of wild-type PKCζ and greatly 
sensitized cells to PN-UVB-induced apoptosis (Fig. 4.13b).  Such observations thus 
provide strong evidence that anti-apoptotic function of PKCζ is achieved via p38 
activation and PN is likely to act through PKCζ to suppress p38 activation and then 

















Figure 4.8 Determination of apoptosis in pDsRed transfected cells.  Apoptotic 
cell death was determined with DNA content/sub-G1 analysis coupled 
with flow cytometry after DAPI staining.  JB6 cells were first 
transiently transfected with various PKC plasmids and pDsRed as a 
transfection marker, followed by treated with PN and UVB. In total of 
20,000 cells from each group analyzed using flow cytometry, only 
those transfected cells with expression of the red fluorescence protein 






































Figure 4.9 Effect of wt- and DN- PKCδ expression on PN-UVB-induced 
apoptosis in JB6 cells. JB6 cells were first transfected for 24 hours, 
followed by treatment with PN and UVB.  Cells were collected for 
DNA content analysis 24 hours after UVB irradiation.  Data were 
presented in means ± SD from 4 independent experiments.  An asterisk 
indicates statistical significance comparing to the group transfected 







































Figure 4.10 Effect of wt- and DN- PKC ζ expression on PN-UVB-induced 
apoptosis in JB6 cells.  JB6 cells were first transfected for 24 hours, 
followed by treatment with PN and UVB.  Cells were collected for 
DNA content analysis 24 hours after UVB irradiation.  Data were 
presented in means ± SD from 4 independent experiments.  An 
asterisk indicates statistical significance comparing to the group 
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Figure 4.11 Effect of PKC on p38 activation in UVB-treated cells. (a) PN and 
pan-specific PKC inhibitor GF109203X, but not the specific PKCδ 
inhibitor rotterlin, inhibited UVB-induced p38 phosphorylation.  Cells 
were pre-treated with 5 µM PN for 2 hours, 20 µM GF109203X or 1 
µM rotterlin for 1 hour and then subjected to 50 mJ/cm2 of UVB.  (b) 
Over-expressions of wt- or DN forms of PKCδ did not affect p38 
activation induced by either UVB alone or PN plus UVB.  (c) Over-
expression of DN- PKCζ blocked UVB-induced p38 activation and 
over-expression of wt-PKCζ reversed the inhibitory effect of PN on 
UVB-induced p38 activation.  JB6 cells were first transiently 
transfected with pcDNA, wt- or DN forms of PKCδ or ζ for 24 hours, 
followed by treatment with PN and UVB.  Cells were harvested 30 
min after UVB irradiation.  Thirty µg of cellular proteins were 
separated on 10% SDS-polyacrylamide gels and the subsequent 
membranes were hybridized with anti- p-p38, p38 and HA antibodies.  
The blots were detected using the enhanced chemiluminescence 
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Figure 4.12 No evident effect of PKC on JNK activation in UVB-treated cells. (a) 
PKC inhibitor GF109203X and rotterlin has no evident effect on 
UVB-induced JNK activation.  JB6 cells were treated as described in 
Fig. 6a.  (b) Over-expressions of DN forms of PKCδ and PKCζ failed 
to affect JNK activation induced by UVB alone or PN plus UVB.  JB6 
cells were transiently transfected with pcDNA, DN forms of PKCδ or 
ζ for 24 hours, followed by treatment with  PN and UVB.  Cells were 
harvested 30 min after UVB irradiation.  Thirty µg of cellular proteins 
were separated on 10% SDS-polyacrylamide gels and the subsequent 
membranes were hybridized with anti- p-p38, p38 and HA antibodies.  
The blots were detected using the enhanced chemiluminescence 












































Figure 4.13 functional relationships between PKCζ and p38 in UVB-induced apoptosis. (a) 
Over-expressions of DN-p38α and DN-p38β2 completely blocked the UVB-induced 
p38 phosphorylation.  JB6 cells were transiently transfected with DN-p38α and DN-
p38β2 for 24 hours, followed by UVB exposure (50 mJ/cm2).  Cells were harvested 
30 min after UVB irradiation.  Thirty µg of cellular proteins were separated on 10% 
SDS-polyacrylamide gels and the subsequent membranes were hybridized with anti- 
p-p38, p38 and Flag antibodies. (b) Over-expressions of DN-p38α and DN-p38β2 
completely abolished the protective effect of wt-PKCζ on apoptosis induced by PN 
and UVB.  Cells were transfected with wt-PKCδ, with or without DN-p38α andDN-
p38β2 for 24 hours, followed by treatment with PN and UVB.  Cells were collected 
for DNA content analysis for sub-G1 cells 24 hours after UVB irradiation.  Data were 
presented in means ± SD from 3 independent experiments.  An asterisk indicates 
statistical significance comparing to the group transfected with pcDNA only (P < 
0.05).   
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4.4 Discussion 
Even though the underlying mechanism(s) of the carcinogenic ability of UVB have 
not been fully understood, a number of molecular targets have been identified to be involved 
in UVB carcinogenesis, which include AP-1, NF-κB, NF-AT, and STATs (Angel et al., 2001; 
Siebenlist et al., 1995; Huang et al., 2000; Zhang et al., 2001).  Results from chapter 2 and 3 
have shown that PN possesses strong chemopreventive property against UVB-induced skin 
cancer via its potent inhibitory effect on the MAPK-AP-1 signaling pathway.  In this study, 
PN has been demonstrated to selectively regulate the activities of PKC: promotion of the pro-
apoptotic PKCδ and suppression of the pro-survival PKCζ.  Moreover, strong evidence 
indicates that PN acts on PKCζ upstream of p38 to sensitize UVB-induced apoptotic cell 
death.  As demonstrated in this part of the study, the results reveal a new mechanism involved 
in the anti-cancer function of PN.  
 PKC can be classified into 11 isoforms based on the co-factors required for activation.  
UVB is known to activate certain PKC isoforms such as PKCδ, ε, ζ, λ/ι, and η, leading to 
apoptosis or cell survival (Chen et al., 1999; Berra et al., 1997; Huang et al., 2000; 
Matsumura et al., 2003).  It has been reported that UVB induces phospholipase A2 activation 
and arachidonic acid release and activates PKC (Blackshear et al., 1988).  Furthermore, UVB 
irradiation of cultured cells is also known to elevate levels of DAG (Punnonen and Yuspa, 
1992) as well as to generate reactive oxygen species that may activate PKC (Sun et al., 2000).  
Among all the UVB-activated PCK isoforms, PKCδ seems to be the main subtype involved 
in apoptotic signaling induced by various stimuli including UVB (Brodie and Blumberg, 
2003).  It is generally believed that activated PKCδ decreases mitochondrial membrane 
potential, resulting in cytochrome c release, caspases activations and apoptosis (Brodie and 
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Blumberg, 2003).  On the other hand, PKCζ has been shown to promote cell survival by 
either stimulating the nucleotide excision repair activity (Louat et al., 2004) or 
phosphorylating Rel A and subsequently activate the NF-κB survival pathway (Duran et al., 
2003).   
One important observation of this study is the differential effect by PN on different PKC 
isoforms in cells treated with UVB: PN selectively enhances the pro-apoptotic PKCδ and 
suppresses the anti-apoptotic PKCζ (Fig. 4.3- 4.6).  Indeed, selective effects on different PKC 
isoforms have been reported previously.  Sodium butyrate has been shown to upregulate 
PKC-ε while downregulate PKC-β during erythroid differentiation (Rivero and Adunyah, 
1998).  UCN-01, a staurosporine analogue, has been illustrated to have selective effect on 
different PKCs isoforms using in vitro kinase assay (Seynaeve et al., 1994).  In addition, a 
diazene carbonyl derivative diamide, which oxidizes thiols to disulfides through 
addition/displacement reactions at the diazene bond, stimulates the pro-apoptotic PKCδ while 
inactivates the oncogenic PKCε (Chu et al., 2003). 
  The differential regulation on PKCδ and ζ is also appreciated by the difference in 
their molecular structures.  Although both PKCs contain an N-terminal regulatory domain 
and a C-terminal catalytic kinase domain, PKCδ contains two cysteine-rich C1 subdomains 
(Jaken, 1996) while PKCζ has only one zinc finger binding region (Ono et al., 1989).  DAG 
is known to bind to one of the cysteine-rich C1 subdomains and activate PKCδ.  In contrast, 
PKCζ is regulated by other lipid cofactors such as phosphatidylinositol (PI) 3,4,5-P3 and 
ceramide (Muller et al., 1995).  At present, the exact mechanisms responsible for the 
differential regulation of PN on UVB-induced PKC activation are not known.  One possible 
explanation is the likely involvement of the caspase cascade in PKC activation.  For 
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instance, PKCδ is cleaved by caspase-3 during apoptosis to a more catalytically active 
fragment (Emoto et al., 1995).  In contrast, caspase-3 dependent cleavage of PKCζ 
generates a fragment that corresponds to its catalytic domain and is enzymatically inactive 
(Frutos et al., 1999).  Since PN is a potent activator of caspase-3 (Wen et al., 2002; Zhang et 
al., 2004a), it is possible that both PKCδ and ζ were cleaved by caspase-3 in response to 
PN-UVB treatment.  As a result, the catalytically active PKCδ and the inactive fragment of 
PKCζ are generated, leading to more profound cell death induced by PN-UVB.    
  Currently, it is still controversial with regards to the exact role of JNK and p38 in 
UV-induced apoptosis, with both pro- and anti-apoptotic activities being reported (Ivanov 
and Ronai, 2000; Tournier et al., 2000; Wisdom et al., 1999).  Previous findings in chapter 
3 indicated that PN sensitizes UVB-induced apoptosis by inhibiting both JNK and p38, 
leading to blockade in the pro-survival AP-1 pathway.  The link between MAPK and PKC 
has been reported previously.  Chen and co-workers (1999) showed that PKCδ and PKCε 
mediate UVB-induced signal transduction and apoptosis through the activation of ERK and 
JNK.  Furthermore, inhibition of PKCλ/ι with a dominant negative mutant suppressed 
UVB-induced ERK and the subsequent AP-1 activation (Huang et al., 1996).  On the other 
hand, antisense oligonucleotide of PKCζ has been shown to inhibit the UVB-induced AP-1 
activation (Huang et al., 2000).  In this study, convincing evidence suggests that PKCζ acts 
upstream of p38, but not JNK, to protect cell death induced by PN-UVB, based on 
experimental data using both pharmacological and genetic approaches.  For instance, over-
expression of wide-type PKCζ reverses the inhibitory effect of PN on UVB-induced p38 
phosphorylation (Fig. 4.11c), and transfections with wild-type PKCζ together with DN-
p38α and DN-p38β2 plasmids completely abolished the protective effect of wild-type PKCζ 
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and greatly sensitized cells to PN-UVB-induced apoptosis (Fig. 4.13b).  Therefore, it is 
clear that the sensitization activity of PN on UVB-induced apoptosis is likely achieved 
through its inhibitory effect on PKCζ and p38 signaling pathway. 
  In summary, the results show for the first time PN sensitizes JB6 cells to UVB-
induced apoptosis through selective regulation on the pro-apoptotic PKCδ and the pro-
survival PKCζ functions.  Furthermore, the data also suggest that the UVB-induced p38 
MAPK activation is regulated via a PKCζ dependent mechanism.  These findings may shed 















PN is the major sesquiterpene lactone in the traditional herbal medicine feverfew 
(Tanacetum parthenium), a plant that has been used for the treatment of fever, migraine, 
and arthritis for centuries (Knight, 1995).  It is believed that PN mediates its effect 
through the highly electrophilic α-methylene-γ-lactone ring and an epoxide residue that 
are capable of interacting rapidly with nucleophillic sites of biological molecules (Macias 
et al., 1997; Zhang et al., 2005).  The anti-microbial and anti-inflammatory properties of 
PN are well studied (Brown et al., 1997; Jain et al., 1999).  However, the anti-cancer 
property of PN has not been fully explored.  Some preliminary studies have shown that 
PN is a potent inhibitor of DNA synthesis and cell proliferation in a number of cancer 
cell lines (Woynarowski and Konopa, 1981; Hall et al., 1988; Ross et al., 1999).  In 
addition, PN has been shown to induce apoptosis in certain cancer cells via caspase 
activation and mitochondria dysfunction (Wen et al., 2002), disruption in intracellular 
thiols and calcium equilibrium (Zhang et al., 2004a), as well as activation of pro-
apoptotic Bcl-2 family proteins (Zhang et al., 2004c).  More recently, PN has been shown 
to reduce metastasis and improve survival in xenograft model of breast cancer when 
applied in combination with docetaxel (Sweeney et al., 2005), as well as preventing 
UVB-induced skin photoaging (Tanaka et al., 2005). 
The objective of this study was to systematically investigate the anti-cancer 
potential of PN using both in vivo animal model and in vitro cell culture.  The following 
studies were conducted: (i) chemopreventive and chemotherapeutic potentials of PN 
using UVB-induced skin cancer model with SKH-1 hairless mice (Chapter 2); (ii) in vitro 
investigation to elucidate the sensitization effect, and the underlining mechanisms of PN 
in UVB-induced apoptosis, in murine epidermal cell line JB6. (Chapter 3 and 4).   
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5.1 Chemopreventive property of PN 
 Prior to this study, the anti-cancer property of PN has never been studied using in 
vivo animal models.  The results from this sudy provide clear evidence that PN possesses 
strong chemopreventive property against UVB-induced skin cancer in female SKH-1 
hairless mice: 1) PN treatment delayed the onset of tumor incidence from week 13th to 
week 18th (Figure 2.5); 2) PN reduced tumor multiplicity by 30% (Figure 2.6); 3) smaller 
papilloma sizes were found in mice treated with PN (Table 2.1); and 4) PN treatment 
reduced the hyperplastic response of the epidermis induced by UVB irradiation (Figure 
2.8).  The chemopreventive capability of PN is found to be as effective as the 
pharmaceutical COX-2 inhibitor celecoxib in preventing UVB-induced 
photocarcinogenesis (Fischer et al., 1999; Pentland et al., 1999).   
 
5.2 Chemotherapeutic property of PN 
On the other hand, the chemotherapeutic activity of parthenolide was also 
evaluated in this model in which parthenolide was applied after the onset of 
photocarcinogenesis. In contrast to its potent chemopreventive activity, parthenolide is 
not an effective chemotherapeutic agent against UVB-induced skin cancer since no 
significant difference in papilloma multiplicity (Figure 2.13) and the size distribution of 
papilloma among different treatment groups (Table 2.2) was detected.   
The exact reason(s) behind PN’s failure as a single chemotherapeutic agent is not 
known.  One of the possibilities could be due to insufficient dosing of PN and a higher 
dosage of PN may be needed in order to achieve any therapeutic effect.  To date, the 
biosafty and bioavailability of PN have not been studied in SKH-1 hairless mice model.  
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Unfortunately, such studies were unable to be conducted due to budgetary constrain.  
Moreover, the route of administration of PN could be a factor that affects our observation.  
It has been shown that celecoxib applied topically results in suppression on UVB-induced 
PGE2 production (Wilgus et al., 2003), while oral route exerts no effect (Fisher et al., 
1999). 
 
5.3 Role of COX-2 in the anti-cancer activity of PN 
COX-2 is the inducible subtype of the enzyme cyclooxygenase (COX) which 
converts free arachidonic acid to prostaglandins (Marnett, 2000).  The fact that UVB 
upregulates COX-2 and prostaglandins production suggests that COX-2 may contribute 
to photocarcinogenesis (Buckman et al., 1998; Grewe et al., 1993).  Preliminary findings 
from our laboratory revealed a positive correlation between cytotoxic response to PN and 
COX-2 expression (unpublished data), which leads us to hypothesize that PN may exert 
its effect in a COX-2-dependent manner. Previous studies have also demonstrated that 
parthenolide is able to suppress COX-mediated pathway either through directly 
inactivating COX-2 enzyme activity (Pugh and Sambo, 1988; Hwang et al., 1996), or by 
indirectly inhibiting COX-2 transcription through NF-κB (Hehner et al., 1998).  However, 
the results from chapter 2 showed that neither treatment of parthenolide nor the specific 
COX-2 inhibitor celecoxib alter COX-2 expression or prostaglandins production induced 
by UVB (Figure 2.9 and 2.10), suggesting that COX-2 is unlikely to be the direct 
molecular target for parthenolide and celecoxib.  This finding is in concordance with an 
earlier report in which long term oral treatment of celecoxib has no effect on UVB-
induced expression of COX-2 (Fischer et al., 1999).  Furthermore, in vitro studies also 
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demonstrated that celecoxib induces apoptosis and cell cycle arrest in a COX-2 
independent manner (Elder et al., 1997; Grosch et al., 2001; Waskewich et al., 2002).  In 
contrary, a recent study reported that topical treatment of celecoxib is as effective as oral 
route in inhibiting UVB-induced skin cancer while also suppressed PGE2 production 
induced by UVB (Wilgus et al., 2003).  It is thus believed parthenolide and celecoxib can 
act via either COX-2 dependent or independent pathways, although the exact molecular 
mechanisms responsible for such effect remain to be further determined.  
In summary, the findings from chapter 2 have demonstrated the chemopreventive 
property of parthenolide against UVB-induced skin cancer in SKH-1 hairless mice.  The 
results also suggested that such chemopreventive activity is probably mediated in a COX-
2-independent manner.   
 
5.4 Anti-cancer potential of PN- sensitization to UVB-induced apoptosis  
The second part of this thesis is to study the underlining mechanisms responsible for 
the chemopreventive property of PN using murine epidermal cell line JB6 with focuses 
on the following two main cell signaling patheways i) AP-1 and the related MAPKs 
signaling cascade, and ii) protein kinase C.   
Apoptosis is an essential cell death process in maintaining development and tissue 
homeostasis.  It is believed that any defects in this important process can result in severe 
pathological diseases and one of the most important outcomes is cancer (Fisher and 
Schulze-Osthoff, 2005).  Dysregulation of apoptosis has also been shown to be crucial in 
the pathogenesis of cancer in many ways such as: (1) allowing neoplastic cells to survive 
beyond their normal lifespan; (2) creating a permissive environment for genetic 
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instability and accumulation of gene mutations; (3) facilitating growth factor- and 
hormone-independent cell survival; (4) promoting resistance to immune-based 
destruction; and (5) conferring resistance to cytotoxic anticancer agents and radiation 
(Reed, 1999). 
Indeed, UV exposure could result in direct or indirect DNA damage, and the damage 
is normally repaired by a nucleotide excision repair (NER) mechanism (Thoma, 1999).  
Most of the irreparable DNA-damaged cells will be eliminated through apoptosis, as 
evident in skin with the appearance of sunburn cells (Kulms and Schwarz, 2002).  
However, not all cells with irreparable DNA damage will undergo apoptosis.  DNA 
lesions that are not repaired or incorrectly repaired may lead to mutations and 
subsequently carcinogenesis.  Therefore, the removal of damaged cells through 
sensitizing cells to apoptosis denotes an effective mean in preventing carcinogenesis 
(Hildesheim et al., 2002; Kulms and Schwarz, 2002; D’Errico et al., 2003).   
 
5.5 Involvement of AP-1 and MAPK in PN-induced sensitization to UVB-induced 
apoptosis 
AP-1 plays a key role in pre-neoplastic to neoplastic transformation in cell culture 
and the blockage of AP-1 activities has been shown to inhibit cell transformation (Dong 
et al., 1994).  Moreover, AP-1 has been shown to regulate apoptosis, with both pro-
apoptotic and anti-apoptotic function (Shaulian and Karin, 2002).  It appears that the 
exact outcome of AP-1 manipulations is highly tissue- and developmental stage-specific.  
In the present study, it has been demonstrated that, in addition to its well known 
suppressive effect on NF-κB (Figure 3.6), PN pre-treatment inhibits the UVB-induced 
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DNA binding (Figure 3.7) and transcriptional activity of AP-1 (Figure 3.8).  Two of the 
major components of AP-1 complex, c-Jun and ATF-2, can activate AP-1 via post-
translational modification involving changes in the phosphorylation states (Buscher et al., 
1988; Devary et al., 1991; van Dam et al., 1995).  In response to UV, c-Jun is rapidly 
phosphorylated at both Ser63 and Ser73 sites along with ATF-2.  The data showed that 
PN subdues UVB-induced AP-1 transactivation via blockage of c-Jun and ATF-2 
phosphorylations (Figure 3.9A and B).  The outcome of these series of inhibitions seem 
to lead to significant sensitization to UVB-induced apoptosis (Figure 3.4), suggesting an 
anti-apoptotic role of AP-1 in UVB-treated cells.   
Similar observations regarding the anti-apoptotic function of AP-1 and c-Jun have 
been reported previously.  Wisdom and co-workers (1999) noted that c-Jun protects cells 
from UV-induced apoptosis and phosphorylation of c-Jun on Ser63 and Ser73 is required 
for such protection.  Moreover, Ivanov and colleagues (2001) demonstrated that c-Jun 
protects cells against UV-induced cell death via co-operation with STAT3 to suppress 
transcription of Fas.   
The UV-activated signal transduction pathway is primarily mediated by mitogen-
activated protein kinases (MAPKs).  Once activated, they translocate to the nucleus and 
phosphorylate target transcription factors.  In response to UV, key MAPKs such as JNK 
and p38 are activated, which in turn phosphorylate c-Jun at Ser-63 and Ser-73 sites and 
ATF-2, respectively (Devary et al., 1991; van Dam et al., 1995).  It is rather controversial 
with regards to the exact role of JNK in UV-mediated apoptosis.  For instance, JNK has 
been shown to be required for UV-induced apoptotic cell death in mouse embryonic 
fibroblasts (Tournier et al., 2000), while other studies demonstrated the anti-apoptotic 
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role of JNK in UV-induced apoptosis (Wisdom et al., 1999; Ivanov et al., 2001).  The 
results from chapter 3 showed that the inhibition of JNK leads to sensitization of JB6 
cells to UVB-induced apoptosis, suggesting an anti-apoptotic role of JNK in the present 
system (Figure 3.11).  In general, the exact role of JNK in apoptosis varies depending on 
a number of factors that include the nature of the stimuli, cell type, the duration of 
activation and more importantly, the interaction of other signaling pathway such as NF-
κB and the PI3K-AKT cascades (Davis, 2000; Lamb et al., 2003; Lin, 2003).  The 
involvement of those cell survival signaling pathways in PN-mediated cell death 
sensitization remains to be further investigated. 
In the present study, the potent inhibitory effect of PN on UVB-induced p38 
activation was also noted (Figure 3.10).  This p38 inhibition leads to sensitization of cells 
to UVB-induced apoptosis (Figure 3.11), implying an anti-apoptotic role of p38 in UVB-
induced apoptotic cell death.  Although it is still controversial regarding the exact role of 
p38 in apoptosis, p38 has been reported to protect cells from UV-induced apoptosis 
through down regulation of NF-κB activity and Fas expression (Ivanov and Ronai, 2000).  
Some other mechanisms have also been proposed to be involved in the anti-apoptotic 
function of p38.  For instance, the p38 MAPK inhibitor SB203580 can trigger a 
significant, Ras-independent activation of c-Raf in certain cell lines in the concentration 
range of 8-25 µM (Hall-Jackson et al., 1999; Kalmes et al., 1999).  Activated Raf may 
phosphorylate and inactivate Bad, a pro-apoptotic member of the Bcl-2 family of proteins, 
or up-regulate the transcription of pro-survival genes to prevent cytochrome c release and 
subsequently apoptosis (Bonni et al., 1999).  Furthermore, Raf-1 has been shown to 
promote cell survival by antagonizing apoptosis signal-regulating kinase 1 (ASK1), an 
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important mediator of apoptotic signaling (Chen et al., 2001).  In the present study, PN 
has been demonstrated to be a dual inhibitor of both JNK and p38 in UVB-treated cells 
(Figure 3.10).  Incidentally, PN-elicited sensitization of JB6 cells to UVB-induced 
apoptosis is twice as strong as with the individual JNK and p38 inhibitor (Figure 3.11).  
These findings suggest that both JNK and p38 contribute to the cell survival mechanisms 
in UVB-treated cells. 
 
5.6 Involvement of PKC in PN-induced sensitization to UVB-induced apoptosis 
Another important molecular target in UVB-mediated signal transduction is protein 
kinase C (PKC).  UVB is known to activate certain PKC isoforms such as PKCδ, ε, ζ, λ/ι, 
and η, leading to apoptosis or cell survival (Chen et al., 1999; Berra et al., 1997; Huang 
et al., 2000; Matsumura et al., 2003).  It has been reported that UVB induces 
phospholipase A2 activation and arachidonic acid release and activates PKC (Blackshear 
et al., 1988).  Furthermore, UVB irradiation of cultured cells is also known to elevate 
levels of DAG (Punnonen and Yuspa, 1992) as well as to generate reactive oxygen 
species that may activate PKC (Sun et al., 2000).  Among all the UVB-activated PKC 
isoforms, PKCδ seems to be the main subtype involved in apoptotic signaling induced by 
various stimuli including UVB (Brodie and Blumberg, 2003).  It is generally believed 
that activated PKCδ decreases mitochondrial membrane potential, resulting in 
cytochrome c release, caspases activations and apoptosis (Brodie and Blumberg, 2003).  
On the other hand, PKCζ has been shown to promote cell survival by either stimulating 
the nucleotide excision repair activity (Louat et al., 2004) or phosphorylating Rel A and 
subsequently activate the NF-κB survival pathway (Duran et al., 2003).   
 130
One important observation of this study is the differential effect by PN on different 
PKC isoforms in cells treated with UVB: PN selectively enhances the pro-apoptotic 
PKCδ and suppresses the anti-apoptotic PKCζ (Fig. 4.3- 4.6).  Indeed, selective effects on 
different PKC isoforms have been reported previously.  Sodium butyrate has been shown 
to upregulate PKC-ε while downregulate PKC-β during erythroid differentiation (Rivero 
and Adunyah, 1998).  UCN-01, a staurosporine analogue, has been illustrated to have 
selective effect on different PKCs isoforms using in vitro kinase assay (Seynaeve et al., 
1994).  In addition, a diazene carbonyl derivative diamide, which oxidizes thiols to 
disulfides through addition/displacement reactions at the diazene bond, stimulates the 
pro-apoptotic PKCδ while inactivates the oncogenic PKCε (Chu et al., 2003). 
  The differential regulation on PKCδ and ζ is also appreciated by the difference in 
their molecular structures.  Although both PKCs contain an N-terminal regulatory 
domain and a C-terminal catalytic kinase domain, PKCδ contains two cysteine-rich C1 
subdomains (Jaken, 1996) while PKCζ has only one zinc finger binding region (Ono et 
al., 1989).  DAG is known to bind to one of the cysteine-rich C1 subdomains and 
activate PKCδ.  In contrast, PKCζ is regulated by other lipid cofactors such as 
phosphatidylinositol (PI) 3,4,5-P3 and ceramide (Muller et al., 1995).  At present, the 
exact mechanisms responsible for the differential regulation of PN on UVB-induced 
PKC activation are not known.  One possible explanation is the likely involvement of 
the caspase cascade in PKC activation.  For instance, PKCδ is cleaved by caspase-3 
during apoptosis to a more catalytically active fragment (Emoto et al., 1995).  In 
contrast, caspase-3 dependent cleavage of PKCζ generates a fragment that corresponds 
to its catalytic domain and is enzymatically inactive (Frutos et al., 1999).  Since PN is a 
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potent activator of caspase-3 (Wen et al., 2002; Zhang et al., 2004a), it is possible that 
both PKCδ and ζ were cleaved by caspase-3 in response to PN-UVB treatment.  As a 
result, the catalytically active PKCδ and the inactive fragment of PKCζ are generated, 
leading to more profound cell death induced by PN-UVB.   
 Currently, it is still controversial with regards to the exact role of JNK and p38 in 
UV-induced apoptosis, with both pro- and anti-apoptotic activities being reported (Ivanov 
and Ronai, 2000; Tournier et al., 2000; Wisdom et al., 1999).  The findings from Chpater 
3 indicated that PN sensitizes UVB-induced apoptosis by inhibiting both JNK and p38, 
leading to blockade in the pro-survival AP-1 pathway.  The link between MAPK and 
PKC has been reported previously.  Chen and co-workers (1999) showed that PKCδ and 
PKCε mediate UVB-induced signal transduction and apoptosis through the activation of 
ERK and JNK.  Furthermore, inhibition of PKCλ/ι with a dominant negative mutant 
suppressed UVB-induced ERK and the subsequent AP-1 activation (Huang et al., 1996).  
On the other hand, antisense oligonucleotide of PKCζ has been shown to inhibit the 
UVB-induced AP-1 activation (Huang et al., 2000).  In this study, convincing evidence 
suggest that PKCζ acts upstream of p38, but not JNK, to protect cell death induced by 
PN-UVB, based on experimental data using both pharmacological and genetic 
approaches.  For instance, over-expression of wide-type PKCζ reverses the inhibitory 
effect of PN on UVB-induced p38 phosphorylation (Fig. 4.11c), and transfections with 
wild-type PKCζ together with DN-p38α and DN-p38β2 plasmids completely abolished 
the protective effect of wild-type PKCζ and greatly sensitized cells to PN-UVB-induced 
apoptosis (Fig. 4.13b).  Therefore, it is clear that the sensitization activity of PN on UVB-





 In this study, the anti-cancer property of PN has been systematically investigated 
in both in vivo animal model and in vitro cell culture.  The main experiments conducted 
were: i) evaluation of the chemopreventive and chemotherapeutic potentials of PN 
against UVB-induced skin cancer in SKH-1 hairless mice model; ii) the PN-sensitized 
UVB-induced apoptosis and the underlining mechanisms.  The major findings of this 
study are: 
1) PN possesses strong chemopreventive property against UVB-induced skin 
cancer in SKH-1 hairless mice.  This chemopreventive property is probably 
mediated in a COX-2 independent manner. 
2) PN is not effective as a single chemotherapeutic agent against UVB-induced 
skin cancer in SKH-1 hairless mice 
3) PN sensitizes murine epidermal cells JB6 to UVB-induced apoptosis via the 
following mechanisms as outlined in Figure 6.1: 
a) PN suppressed the UVB-induced JNK and p38 kinase activations, 
leading to the downstream inhibitions of c-Jun at Ser-63 and Ser-73 as 
well as ATF-2.  Such suppressions are capable of inhibiting the pro-
survival transcription factor AP-1, leading to sensitization of cells to 
UVB-induced apoptosis. 
b) PN selectively enhances the pro-apoptotic PKCδ and suppresses the 
anti-apoptotic PKCζ.  Furthermore, PKCζ acts upstream of p38, but 
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not JNK, to protect cell death induced by PN and UVB 
In summary, the new findings in this study demonstrate the potent anti-cancer 
property of PN in addition to its well-known anti-inflammatory action.  The experimental 
evidences suggest that PN, the major sesquiterpene lactone in feverfew, is a promising 






Figure 5.1 Mechanisms involved in PN-sensitized UVB-induced apoptosis.  (A) 
PN is capable of sensitizing cells to UVB-induced cell death by 
inhibiting JNK and p38 kinase activation, blocking the downstream 
phosphorylations of c-Jun and ATF-2, and thus suppressing the pro-
survival transcription factor AP-1.  (B) PN selectively enhances the 
pro-apoptotic PKCδ while suppresses the anti-apoptotic PKCζ.  The 
suppression on PKCζ will then lead to inhibition on p38 kinase and 
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